

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/037899 A1

(51) International Patent Classification⁷: C07D 487/04,
A61K 31/505, A61P 9/00, 15/00

John [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
WOOD, Anthony [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(21) International Application Number: PCT/IB02/04385

(22) International Filing Date: 22 October 2002 (22.10.2002)

(74) Agents: **WOOD, David, J.** et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(30) Priority Data:
0126395.3 2 November 2001 (02.11.2001) GB
0130695.0 21 December 2001 (21.12.2001) GB
0216761.7 18 July 2002 (18.07.2002) GB

(71) Applicant (*for GB only*): **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except GB, US*): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DENINNO, Michael, Paul** [US/US]; Pfizer Inc., Central Research Division, Eastern Point Road, Groton, CT 06340 (US). **HUGHES, Bernadette** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **KEMP, Mark, Ian** [GB/GB]; Pfizer Central Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **PALMER, Michael,**


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/037899 A1

(54) Title: PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS



(I)

(57) Abstract: The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula (I) wherein R¹ is H or C₁₋₆ alkyl, wherein R¹ is attached to either N¹ or N²; R² is C₁₋₆ alkyl optionally substituted by hydroxy or alkoxy; C₃₋₇ cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het¹ or Ar¹; R³ is C₁₋₆ alkyl optionally substituted by 1 or 2 groups independently selected from: Ar²; C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkyl; OAr²; SAR²; Sar²; NHC(O)C₁₋₆ alkyl; het²; xanthene; and naphthalene (I).

PDE9 inhibitors for Treating Cardiovascular Disorders

This invention relates to the novel use of cyclic guanylate monophosphate (cGMP)-specific phosphodiesterase type 9 inhibitors (hereinafter referred to as
5 PDE9 inhibitors) for treating a variety of diseases, particularly cardiovascular diseases. In addition, the invention relates to novel PDE9 inhibitors, to processes for preparing them, intermediates used in their preparation, and compositions containing them.

10 The phosphodiesterase enzyme family hydrolyses cyclic nucleotides cGMP and cyclic adenosine monophosphate (cAMP). cGMP and cAMP are central to the control and regulation of a multitude of cellular events, both physiological and pathophysiological.

15 D A Fisher *et al* [J. Biol. Chemistry, vol 273, No 25, 15559 -15564 (1998)] identified the PDE9 enzyme as a novel member of the PDE enzyme family that selectively hydrolyses cGMP over cAMP. PDE9 was found to be present in a variety of human tissues, namely the testes, brain, small intestine, skeletal muscle, heart, lung, thymus and spleen. Smooth muscle cells in the human
20 vasculature were not analysed for the presence of PDE9.

We have now found the presence of PDE9 in smooth muscle cells within the human vasculature of a variety of tissues.

25 Therefore according to a first aspect, the invention provides the use of a PDE9 inhibitor in the manufacture of a medicament for treating or preventing a cardiovascular disorder, disease or condition.

Preferably the cardiovascular disorder, disease or condition is selected from:
30 systemic (or essential) hypertension, pulmonary hypertension (e.g. pulmonary arterial hypertension, pulmonary hypertension of the neonate), congestive heart failure, coronary artery disease, atherosclerosis, stroke, thrombosis, conditions of reduced blood vessel patency (for example post percutaneous transluminal

coronary angioplasty), peripheral vascular disease, renal disease (especially that occurring with diabetes), angina (including stable, unstable and variant (Prinzmetal) angina), myocardial ischaemia and any condition where improved blood flow leads to improved end organ function. More preferably the

5 cardiovascular disease is systemic hypertension.

Alternatively the cardiovascular disease may be associated with other conditions, particularly hypertension associated with diabetes.

10 According to a further aspect there is provided the use of a PDE9 inhibitor in the manufacture of a medicament for treating a condition selected from: male sexual dysfunction (particularly male erectile dysfunction otherwise known as impotence); female sexual dysfunction (FSD) (particularly female hypoactive

15 sexual desire disorder, female sexual arousal disorder, female sexual pain disorder, female orgasmic dysfunction, clitoral dysfunction, dysfunction caused by spinal cord injury and selective serotonin re-uptake inhibitor induced sexual dysfunction), premature labour, dysmenorrhoea, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, nitrate induced tolerance, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, diseases and conditions of the

20 eye (for example glaucoma and optic neuropathy, macular degeneration, elevated intra-ocular pressure, retinal or arterial occlusion), diseases characterised by disorders of gut motility (for example irritable bowel syndrome), pre-eclampsia, Kawasaki's syndrome, nitrate tolerance, multiple sclerosis, neuropathy (including autonomic and peripheral neuropathy), Alzheimer's

25 disease, acute respiratory failure, psoriasis, skin necrosis, cancer, metastasis, baldness, nutcracker oesophagus, anal fissures, haemorrhoids, hypoxic vasoconstriction and stabilisation of blood pressure during haemodialysis.

Without being bound by any theory, we believe that PDE9 inhibitors treat

30 cardiovascular diseases by acting on the nitric oxide/cGMP pathway to mediate relaxation of vascular smooth muscle, thereby causing hypotension, augmenting vascular flow and thus protecting end organ function in disease states where blood flow is compromised.

Preferably (using the assay described hereinafter) the PDE9 inhibitor has a greater than 40% inhibition against PDE9 at a concentration of 1 μ M. More preferably the PDE9 inhibitor has an IC_{50} of less than 500 nM, most preferably an IC_{50} of less than 50nM. Preferably the PDE9 inhibitor has a selectivity for PDE9 over PDE1 of greater than 10, preferably greater than 50, most preferably greater than 100.

Preferably the PDE9 inhibitors of the invention are bioavailable when taken orally. Oral bioavailability refers to the proportion of an orally administered drug that reaches the systemic circulation. The factors that determine oral bioavailability of a drug are dissolution, membrane permeability and metabolic stability. Typically, a screening cascade of firstly *in vitro* and then *in vivo* techniques is used to determine oral bioavailability.

Dissolution, the solubilisation of the drug by the aqueous contents of the gastrointestinal tract (GIT), can be predicted from *in vitro* solubility experiments conducted at appropriate pH to mimic the GIT. Preferably the PDE9 inhibitors have a minimum solubility of 50 μ g/ml. Solubility can be determined by standard procedures known in the art such as described in Lipinski CA et al.; Adv. Drug Deliv. Rev. 23(1-3), 3-25, 1997.

Membrane permeability refers to the passage of a compound through the cells of the GIT. Lipophilicity is a key property in predicting this and is defined by *in vitro* Log $D_{7.4}$ measurements using organic solvents and buffer. Preferably the PDE9 inhibitors have a Log $D_{7.4}$ of -2 to +4, more preferably -1 to +3. The Log D can be determined by standard procedures known in the art such as described in Stopher, D and McClean, S; J. Pharm. Pharmacol. 42(2), 144, 1990.


Cell monolayer assays such as Caco2 add substantially to prediction of favourable membrane permeability in the presence of efflux transporters such as P-glycoprotein, so-called Caco2 flux. Preferably, the PDE9 inhibitors have a Caco2 flux of greater than $2 \times 10^{-6} \text{cms}^{-1}$, more preferably greater than $5 \times 10^{-6} \text{cms}^{-1}$.

The Caco2 flux value can be determined by standard procedures known in the art such as described in Artursson, P and Magnusson, C; J. Pharm. Sci, 79(7), 595-600, 1990.

- 5 Metabolic stability addresses the ability of the GIT or the liver to metabolise compounds during the absorption process: the first pass effect. Assay systems such as microsomes, hepatocytes etc are predictive of metabolic lability. Preferably the PDE9 inhibitors show metabolic stability in the assay system that is commensurate with an hepatic extraction of less then 0.5. Examples of assay
10 systems and data manipulation are described in Obach, RS; Curr. Opin. Drug Disc. Devel. 4(1), 36-44, 2001 and Shibata, Y *et al.*; Drug Met. Disp. 28(12), 1518-1523, 2000.

- Because of the interplay of the above processes, further support that a drug will
15 be orally bioavailable in humans can be gained by *in vivo* experiments in animals. Absolute bioavailability is determined in these studies by administering the compound separately or in mixtures by the oral route. For absolute determinations (% absorbed) the intravenous route is also employed. Examples of the assessment of oral bioavailability in animals can be found in Ward, KW *et al.*;
20 Drug Met. Disp. 29(1), 82-87, 2001; Berman, J *et al.*; J. Med. Chem. 40(6), 827-829, 1997 and Han KS and Lee, MG; Drug Met. Disp. 27(2), 221-226, 1999.

A preferred PDE9 inhibitor is a compound of formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof



25

wherein

R¹ is H or C₁₋₆ alkyl, wherein R¹ is attached to either N¹ or N²;

R² is C₁₋₆ alkyl optionally substituted by hydroxy or alkoxy; C₃₋₇ cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-

30


membered heterocycle (preferably tetrahydrofuran, tetrahydrothiophene,

pyrrolidine or piperidine) optionally substituted by alkyl, hydroxy or alkoxy; het¹ or Ar¹;

R³ is C₁₋₆ alkyl optionally substituted by 1 or 2 groups independently selected from: Ar²; C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl; OAr²; SAR²;

5 NHC(O)C₁₋₆ alkyl; het²; xanthene; and naphthalene;

wherein Ar¹ and Ar² are independently groups of formula



10 wherein R⁴, R⁵ and R⁶ are independently selected from: hydrogen, halo, phenoxy, phenyl, CF₃, OCF₃, R⁷, SR⁷ and OR⁷, wherein R⁷ is C₁₋₆ alkyl optionally substituted by het³ or by a phenyl group optionally substituted by 1,2 or 3 groups independently selected from halo, CF₃, OCF₃, C₁₋₆ alkyl and C₁₋₆ alkoxy; or wherein R⁴ and R⁵ combine to form a 3 or 4 atom link, wherein said link may incorporate one or two heteroatoms independently selected from O, S and N; and



15 wherein het¹, het² and het³, which may be the same or different, are aromatic 5-6 membered heterocycles containing 1, 2 or 3 heteroatoms, independently selected from O, S and N, said heterocycle optionally substituted by 1, 2 or 3 substituents, independently selected from C₁₋₆ alkyl, C₁₋₆alkoxy, halo and phenyl optionally substituted by 1, 2 or 3 groups independently selected from halo and C₁₋₆ alkyl;

20 with the provisos that when


a) R¹ is attached to N¹, R¹ is C₁₋₃ alkyl and R² is propyl then R³ is not methyl substituted by Ar¹, and

25 b) R¹ is attached to N¹, R¹ is C₁₋₆ alkyl and R² is methyl then R³ is not C₁₋₄alkyl substituted by Ar¹.

It will be appreciated by the skilled chemist that compounds represented by general formula I cover both compounds of formula Ia and Ib



A more preferred PDE9 inhibitor is a compound of formula Ia, a pharmaceutically acceptable salt, solvate or prodrug thereof




5 wherein

R^1 is H or C_{1-6} alkyl;

R^2 is C_{1-6} alkyl optionally substituted by hydroxy or alkoxy; C_{3-7} cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle (preferably tetrahydrofuran, tetrahydrothiophene, pyrrolidine or piperidine) optionally substituted by alkyl, hydroxy or alkoxy;
 10 het^1 or Ar^1 ;

R^3 is C_{1-6} alkyl optionally substituted by 1 or 2 groups independently selected from: Ar^2 ; C_{3-7} cycloalkyl optionally substituted by C_{1-6} alkyl; OAr^2 ; SAr^2 ; $NHC(O)C_{1-6}$ alkyl; het^2 ; xanthene; and naphthalene;

15 wherein Ar^1 and Ar^2 are independently groups of formula



wherein R^4 , R^5 and R^6 are independently selected from: hydrogen, halo, phenoxy, phenyl, CF_3 , OCF_3 , R^7 , SR^7 and OR^7 , wherein R^7 is C_{1-6} alkyl optionally substituted by het^3 or by a phenyl group optionally substituted by
 20 1, 2 or 3 groups independently selected from halo, CF_3 , OCF_3 , C_{1-6} alkyl and C_{1-6} alkoxy; or wherein R^4 and R^5 combine to form a 3 or 4 atom link, wherein said link may incorporate one or two heteroatoms independently selected from O, S and N; and

wherein het^1 , het^2 and het^3 , which may be the same or different, are aromatic 5-6 membered heterocycles containing 1, 2 or 3 heteroatoms, independently selected from O, S and N, said heterocycle optionally substituted by 1, 2 or 3 substituents, independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, halo and phenyl optionally substituted by 1, 2 or 3 groups independently selected from halo and C_{1-6} alkyl;

with the provisos that when


a) R^1 is C_{1-3} alkyl and R^2 is propyl then R^3 is not methyl substituted by Ar^1 , and

b) R^1 is C_{1-6} alkyl and R^2 is methyl then R^3 is not C_{1-4} alkyl substituted by Ar^1 .

10

In a further embodiment the invention provides a compound of formula Ia, wherein R^1 is H or C_{1-6} alkyl; R^2 is selected from C_{1-6} alkyl, straight chain or branched chain, C_{3-7} cycloalkyl and heteroaryl; R^3 is C_{1-6} alkyl, straight chain or branched chain, optionally substituted by 1-2 groups each independently selected from: Ar, C_{3-7} cycloalkyl, OAr, SAR, NC(O)C_{1-6} alkyl, heteroaryl, xanthene and naphthalene, wherein:

Ar is a group of formula



wherein R^4 , R^5 and R^6 are each independently selected from: H, halo, OPh, Ph, CF_3 , OCF_3 , SC_{1-6} alkyl, C_{1-6} alkyl, OC_{1-6} alkyl, said alkyl optionally substituted by a heteroaryl group or by a Ph group, wherein said Ph group is optionally substituted by 1-3 groups selected from halo, CF_3 , OCF_3 and C_{1-6} alkyl; or wherein R^4 and R^5 may combine to form a C_{1-3} alkyl link, wherein said link may optionally incorporate one or two heteroatoms selected from O, S and N, wherein heteroaryl is aromatic 5-6 membered heterocycle containing 1-3 heteroatoms, each independently selected from O, S and N, said heterocycle optionally substituted by 1-3 substituents, each independently selected from C_{1-6} alkyl, halo and Ph, said Ph optionally substituted by 1-3 groups selected from halo and C_{1-6} alkyl; with the proviso that when R^1 is $-\text{CH}_3$, R^2 cannot be $-\text{CH}_2\text{CH}_2\text{CH}_3$; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

Unless otherwise indicated, any alkyl group may be straight or branched and is of 1 to 6 carbon atoms, preferably 1 to 4 and particularly 1 to 3 carbon atoms.

Halo means fluoro, chloro, bromo or iodo.

5

Preferably R^1 is hydrogen or CH_3 . More preferably R^1 is hydrogen.

Preferably R^2 is C_{3-4} alkyl, cyclopentyl or pyridyl. More preferably R^2 is 3-pyridyl.

- 10 Preferably R^3 is C_{1-3} alkyl optionally substituted by 1 or 2 groups independently selected from: Ar^2 , C_{3-7} cycloalkyl optionally substituted by C_{1-6} alkyl and het^2 .
More preferably R^3 is C_{1-3} alkyl optionally substituted by Ar^2 . Most preferably R^3 is methyl substituted by Ar^2 .

- 15 Preferably R^4 , R^5 and R^6 are independently selected from: hydrogen, halo, phenoxy, phenyl, CF_3 , OCF_3 , R^7 , SR^7 , and OR^7 , wherein R^7 is C_{1-6} alkyl optionally substituted by a het^3 group or by a phenyl group optionally substituted by 1,2 or 3 groups independently selected from halo, CF_3 , OCF_3 , C_{1-6} alkyl and C_{1-6} alkoxy; or wherein R^4 and R^5 combine to form a 3 atom link wherein said link contains an
20 oxygen atom.

More preferably R^4 , R^5 and R^6 are independently selected from hydrogen, halo, CF_3 , OCF_3 , phenoxy, and OC_{1-6} alkyl optionally substituted by phenyl optionally substituted by halo, CF_3 , OCF_3 or C_{1-6} alkyl.

25

Yet more preferably R^4 , R^5 and R^6 are independently selected from hydrogen, chloro, OCF_3 , CF_3 , phenoxy and OC_{1-6} alkyl substituted by phenyl.

- Most preferably, R^4 , R^5 and R^6 are independently selected from hydrogen, chloro,
30 OCF_3 and OC_{1-3} alkyl substituted by phenyl.

Preferably het^2 is an aromatic 5-6 membered heterocycle containing 1 or 2 nitrogen atoms optionally containing a further heteroatom, said heterocycle being

optionally substituted by 1, 2 or 3 substituents, each independently selected from C₁₋₆ alkyl, halo and phenyl optionally substituted by 1, 2 or 3 groups independently selected from halo and C₁₋₆ alkyl.

- 5 More preferably het² is an aromatic 5-membered heterocycle containing 1 or 2 nitrogen atoms optionally containing a further heteroatom, said heterocycle being optionally substituted by 1 substituent selected from C₁₋₆ alkyl, halo and phenyl optionally substituted by 1, 2 or 3 groups independently selected from halo and C₁₋₆ alkyl.

10

Yet more preferably het² is an aromatic 5 membered heterocycle containing 1 or 2 nitrogen atoms optionally containing a further heteroatom and optionally substituted by phenyl optionally substituted by halo.

- 15 Most preferably het² is imidazolyl or oxadiazolyl.

Preferred compounds are:

5-(3-chlorobenzyl)-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
(compound 1);

- 20 3-isopropyl-5-(2-phenoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
(compound 52);

3-(3-pyridinyl)-5-(2-benzyloxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
(compound 138);

- 25 3-isopropyl-5-(2-trifluoromethoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
(compound 156);

3-cyclopentyl-5-(2-benzyloxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
(compound 204);

3-(3-pyridinyl)-5-(2-trifluoromethylbenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
(compound 215);

- 30 3-cyclopentyl-5-(2-trifluoromethoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
(compound 258); and

3-(3-pyridinyl)-5-(2-trifluoromethoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
(compound 260).

Compounds of formula I as defined hereinabove in the various embodiments of the first aspect are novel. Therefore according to a second aspect, the invention provides a compound of formula I, a pharmaceutically acceptable salt, solvate or
5 prodrug thereof defined hereinabove in the various embodiment of the first aspect.

For the avoidance of doubt, unless otherwise indicated, the term substituted means substituted by one or more defined groups.

10

For the avoidance of doubt, the term independently means that where more than one substituent is selected from a number of possible substituents, those substituents may be the same or different.

15 The pharmaceutically acceptable salts of the compounds of formula I which contain a basic centre are, for example, non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acid, with carboxylic acids or with organo-sulfonic acids. Examples include the HCl, HBr, HI, sulfate or bisulfate, nitrate, phosphate or hydrogen
20 phosphate, acetate, benzoate, succinate, saccharate, fumarate, maleate, lactate, citrate, tartrate, gluconate, camsylate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate salts. Compounds of formula I which contain an acidic centre can provide pharmaceutically acceptable metal salts, in particular non-toxic alkali and alkaline earth metal salts, with bases.
25 Examples include the sodium, potassium, aluminium, calcium, magnesium and zinc salts. Alternatively organic salts can be made, for example the diethanolamine salt. For reviews on suitable pharmaceutical salts see Berge *et al*, J. Pharm, Sci., 66, 1-19, 1977; P L Gould, International Journal of Pharmaceutics, 33 (1986), 201-217; and Bighley *et al*, Encyclopaedia of
30 Pharmaceutical Technology, Marcel Dekker Inc, New York 1996, Volume 13, page 453-497.

The pharmaceutically acceptable solvates of the compounds of formula I include hydrates thereof.

Also included within the scope of the invention and various salts of the invention
5 are polymorphs thereof.

Hereinafter, compounds of formula I, their pharmaceutically acceptable salts, their solvates or polymorphs are referred to as "compounds of the invention".

10 The compounds of the invention may possess one or more chiral centres and so exist in a number of stereoisomeric forms. All stereoisomers and mixtures thereof are included in the scope of the present invention. Racemic compounds may either be separated using preparative HPLC and a column with a chiral stationary phase or resolved to yield individual enantiomers utilising methods known to
15 those skilled in the art. In addition, chiral intermediate compounds may be resolved and used to prepare chiral compounds of the invention.

The compounds of the invention may exist in one or more tautomeric forms. All tautomers and mixtures thereof are included in the scope of the present
20 invention. For example, a claim to 2-hydroxypyridinyl would also cover its tautomeric form, α -pyridonyl.

It will be appreciated by those skilled in the art that certain protected derivatives of compounds of the invention, which may be made prior to a final deprotection stage,
25 may not possess pharmacological activity as such, but may, in certain instances, be administered orally or parenterally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". Further, certain compounds of the invention may act as prodrugs of other compounds of the invention. All
30 protected derivatives and prodrugs of compounds of the invention are included within the scope of the invention. Examples of suitable pro-drugs for the compounds of the present invention are described in Drugs of Today, Volume 19, Number 9, 1983, pp 499 – 538 and in Topics in Chemistry, Chapter 31, pp 306 –

316 and in "Design of Prodrugs" by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures in which documents are incorporated herein by reference). It will further be appreciated by those skilled in the art, that certain moieties, known to those skilled in the art as "pro-moieties", for example as described by H. Bundgaard in

5 "Design of Prodrugs" (the disclosure in which document is incorporated herein by reference) may be placed on appropriate functionalities when such functionalities are present within compounds of the invention. Preferred prodrugs for compounds of the invention include: esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds,

10 phosphamides, glycosides, ethers, acetals and ketals.

The invention also includes all suitable isotopic variations of a compound of the invention. An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic

15 number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F and ^{36}Cl , respectively. Certain isotopic variations of the invention, for

20 example, those in which a radioactive isotope such as ^3H or ^{14}C is incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., ^2H , may afford certain therapeutic advantages resulting from

25 greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the compounds of the invention can generally be prepared by conventional procedures such as by the illustrative methods or by the preparations described in the Examples and Preparations hereafter using

30 appropriate isotopic variations of suitable reagents.


Compounds of the invention may be prepared by the following reaction schemes. In the following reaction schemes and hereafter, unless otherwise stated, R^1 to R^7

are as defined in the first aspect. These processes form further aspects of the invention.

Throughout the specification, general formulae are designated by Roman numerals I, II, III, IV etc. Subsets of these general formulae are defined as Ia, Ib, Ic etc, IVa, IVb, IVc etc.

Compounds of general formula I may be prepared from compounds of general formula II according to reaction scheme 1. Suitable conditions are well known to a man skilled in the art and include base catalysed cyclisation using reagents such as potassium tert-butoxide, sodium hydroxide and potassium carbonate in an alcoholic solvent such as ethanol or isopropanol or an alcohol/water mixture. The reaction may be carried out at a temperature between room temperature and the reflux temperature of the solvent, optionally in the presence of hydrogen peroxide.


Scheme 1



Compounds of general formula II may be prepared according to reaction scheme 2, by reacting compounds of formula IV with compounds of formula III. Such amide bond forming reactions may be carried out under a wide variety of conditions well known to the skilled man. For example, compounds of formula IV may be activated by treatment with an agent such as 1,1-carbonyldiimidazole (CDI) or fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TFFH), or a combination of agents such as azabenzotriazol-1-yloxytris(pyrrolidino)-phosphonium hexafluorophosphate (PyAOP) and 1-hydroxy-7-azabenzotriazole (HOAt), followed by addition of the compound of formula III.

Alternatively, the reaction shown in reaction scheme 2 may be carried out by addition of a peptide coupling agent such as O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) to a mixture of the compounds of formula III and IV. This reaction is carried out in a suitable solvent such as dichloromethane, pyridine, N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA) or 1-methyl-2-pyrrolidinone at a temperature between 0°C and the reflux temperature of the solvent. The reaction is preferentially carried out by activation of the compound of formula IV with CDI in pyridine under refluxing conditions.

Scheme 2



Compounds of general formula III may be prepared from easily obtained starting materials using processes described in the preparative examples hereinafter and described in European Patent EP0463756.

Compounds of general formula IV may be prepared from easily obtained starting materials using processes similar to those described in the preparative examples hereinafter. In addition many compounds of general formula IV are commercially available.

A pharmaceutically acceptable salt of a compound of the formula I may be readily prepared by mixing together solutions of a compound of the formula I and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

The compounds of the invention can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

5

For example, the compounds of the invention can be administered orally, buccally or sublingually in the form of tablets, capsules, multi-particulates, gels, films, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications. The compounds of the invention may also be administered as fast-dispersing or fast-dissolving dosage forms or in the form of a high energy dispersion or as coated particles. Suitable formulations of the compounds of the invention may be in coated or uncoated form, as desired.

Such solid pharmaceutical compositions, for example, tablets, may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably corn, potato or tapioca starch), disintegrants such as sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

25 General Example

A formulation of the tablet could typically contain between about 0.01 mg and 500 mg of active compound whilst tablet fill weights may range from 50 mg to 1000 mg. An example of a formulation for a 10mg tablet is illustrated below:

30	Ingredient	%w/w
	Compound of formula I	10.000*
	Lactose	64.125

Starch	21.375
Croscarmellose sodium	3.000
Magnesium Stearate	1.500

- 5 * Quantity adjusted in accordance with drug activity.

The tablets are manufactured by a standard process, for example, direct compression or a wet or dry granulation process. The tablet cores may be coated with appropriate overcoats.

10

Solid compositions of a similar type may also be employed as fillers in gelatin or HPMC capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the invention may be combined
15 with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

20

Modified release and pulsatile release dosage forms may contain excipients such as those detailed for immediate release dosage forms together with additional excipients that act as release rate modifiers, these being coated on and/or included in the body of the device. Release rate modifiers include, but are not exclusively limited to, hydroxypropylmethyl cellulose, methyl cellulose, sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, polyethylene oxide,
25 Xanthan gum, Carbomer, ammonio methacrylate copolymer, hydrogenated castor oil, carnauba wax, paraffin wax, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, methacrylic acid copolymer and mixtures thereof. Modified release and pulsatile release dosage forms may contain one or a combination of release rate modifying excipients. Release rate
30 modifying excipients may be present both within the dosage form i.e. within the matrix, and/or on the dosage form, i.e. upon the surface or coating.

Fast dispersing or dissolving dosage formulations (FDDFs) may contain the following ingredients: aspartame, acesulfame potassium, citric acid, croscarmellose sodium, crospovidone, diascorbic acid, ethyl acrylate, ethyl cellulose, gelatin, hydroxypropylmethyl cellulose, magnesium stearate, mannitol, methyl methacrylate, mint flavouring, polyethylene glycol, fumed silica, silicon dioxide, sodium starch glycolate, sodium stearyl fumarate, sorbitol, xylitol. The terms dispersing or dissolving as used herein to describe FDDFs are dependent upon the solubility of the drug substance used i.e. where the drug substance is insoluble a fast dispersing dosage form can be prepared and where the drug substance is soluble a fast dissolving dosage form can be prepared.

The compounds of the invention can also be administered parenterally, for example, intracavernously, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion or needleless injection techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

The following dosage levels and other dosage levels herein are for the average human subject having a weight range of about 65 to 70 kg. The skilled person will readily be able to determine the dosage levels required for a subject whose weight falls outside this range, such as children and the elderly.

For oral and parenteral administration to human patients, the daily dosage level of the compounds of the invention will usually be from 0.01 mg to 500 mg (in single or divided doses).

Thus tablets or capsules of the compound of the invention may contain from 0.01 mg to 500 mg (for example 10 mg to 250 mg) of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention. The skilled person will appreciate that the compounds of the invention may be taken as a single dose as needed or desired.

The compounds of the invention can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomiser or nebuliser, with or without the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A [trade mark]) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA [trade mark]), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray, atomiser or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

Aerosol or dry powder formulations are preferably arranged so that each metered dose or "puff" contains from 1 µg to 50 mg of a compound of the invention for delivery to the patient. The overall daily dose with an aerosol will be in the range of from 1 µg to 50 mg which may be administered in a single dose or, more usually, in divided doses throughout the day.

Alternatively, the compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The compounds of the invention may also be dermally or transdermally administered, for example,
5 by the use of a skin patch. They may also be administered by the pulmonary or rectal routes.

They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH
10 adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

15 For application topically to the skin, the compounds of the invention can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can
20 be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

25 The compounds of the invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most
30 dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most

commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

5 The present invention additionally comprises the combination of a PDE9 inhibitor, (particularly a compound of formula I as defined in the various embodiments of the first aspect) and one or more additional active agent selected from:

- a) a PGI₂ prostaglandin, such as prostacyclin or iloprost;
- b) an α - adrenergic receptor antagonist compound also known as α -
10 adrenoceptor antagonists, α -receptor antagonists or α -blockers; suitable compounds for use herein include: the α -adrenergic receptor antagonists as described in PCT application WO99/30697 published on 14th June 1998, the disclosures of which relating to α -adrenergic receptor antagonists are incorporated herein by reference and include, selective α_1 -adrenoceptor
15 antagonists or α_2 -adrenoceptor antagonists and non-selective adrenoceptor antagonists, suitable α_1 -adrenoceptor antagonists include: phentolamine, phentolamine mesylate, trazodone, alfuzosin, indoramin, naftopidil, tamsulosin, dapiprazole, phenoxybenzamine, idazoxan, efaraxan, yohimbine, rauwolfia alkaloids, Recordati 15/2739, SNAP 1069, SNAP 5089, RS17053, SL 89.0591,
20 doxazosin, terazosin, abanoquil and prazosin; α_2 -blockers from US 6,037,346 [14th March 2000] dibenarnine, tolazoline, trimazosin and dibenarnine; α -adrenergic receptors as described in US patents: 4,188,390; 4,026,894; 3,511,836; 4,315,007; 3,527,761; 3,997,666; 2,503,059; 4,703,063; 3,381,009; 4,252,721 and 2,599,000 each of which is incorporated herein by reference; α_2 -
25 adrenoceptor antagonists include: clonidine, papaverine, papaverine hydrochloride, optionally in the presence of a cariotonic agent such as pirxamine;
- c) an NO-donor (NO-agonist) compound; suitable NO-donor compounds for use herein include organic nitrates, such as mono- di or tri-nitrates or organic nitrate esters including glyceryl trinitrate (also known as nitroglycerin), isosorbide
30 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside (SNP), 3-morpholinomethylmolsidomine, S-nitroso- N-acetyl penicillamine (SNAP) S-nitroso-N-glutathione (SNO-GLU), N-hydroxy - L-arginine, amylnitrate, linsidomine, linsidomine chlorohydrate, (SIN-1)

S-nitroso - N-cysteine, diazenium diolates, (NONOates), 1,5-pentanedinitrate, L-arginine, ginseng, zizphi fructus, molsidomine, Re – 2047, nitrosylated maxisylate derivatives such as NMI-678-11 and NMI-937 as described in published PCT application WO 0012075;

- 5 d) a potassium channel opener; suitable potassium channel openers for use herein include nicorandil, cromokalim, levcromakalim, lemakalim, pinacidil, cliazoxide, minoxidil, charybdotoxin, glyburide, 4-aminopyridine, barium chloride;
- e) a compound which modulates the action of atrial natriuretic factor (also known as atrial natriuretic peptide), such as inhibitors of neutral endopeptidase
- 10 (NEP);
- f) a compound which inhibits angiotensin-converting enzyme (ACE) (such as alacepril, alindapril, altiopril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, cilazaprilat, delapril, enalapril, enalaprilat, fosinopril, imidapril, indolapril, libenzapril, lisinopril, moexepiril, moveltipril, pentopril, perindopril,
- 15 quinapril, quinaprilat, ramipril, rentiapril, spirapril, temocapril, teprotide, trandolapril and zofenopril) or a dual ACE/NEP inhibitor, i.e. a compound that inhibits both ACE and NEP (such as, for example, omapatrilat, fasidotril, mixanpril, BMS-189921, MDL-100240 and Z13752A).
- g) an angiotensin II receptor blocker (ARB) such as candesartan, eprosartan,
- 20 irbesartan, losartan, olmesartan, olmesartan medoxomil, saralasin, telmisartan and valsartan.
- h) a substrate for NO-synthase, such as L-arginine;
- i) a calcium channel blocker such as amlodipine, verapamil, pranidipine, azelnidipine and vatanidipine;
- 25 j) an antagonist of endothelin receptors or an inhibitor of endothelin-converting enzyme;
- k) a cholesterol lowering agent such as statins. Examples of statins are atorvastatin calcium (Lipitor), cerivastatin sodium (Baycol), fluvastatin sodium (Lescol), lovastatin (Mevacor), pravastatin sodium (Pravachol) and simvastatin
- 30 (Zocor)
- l) an antiplatelet or antithrombotic agent, e.g. tPA, uPA, warfarin, hirudin and other thrombin inhibitors, aspirin, plavix, cilostazol, heparin, thromboplastin activating factor inhibitors;

- m) a PDE5 inhibitor (such as 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one (sildenafil); (6*R*,12*aR*)-2,3,6,7,12,12*a*-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-*b*]indole-1,4-dione (tadalafil, IC-351); 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3*H*-imidazo[5,1-*f*][1,2,4]triazin-4-one (vardenafil); 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one; and 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one); and
- n) a beta-blocker, diuretic or aldosterone antagonist.

If a combination of active agents are administered, then they may be administered simultaneously, separately or sequentially.


It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.

In a further aspect there is provided a method of treating a cardiovascular disorder in a mammal wherein the mammal is treated with an effective amount of a PDE9 inhibitor. The preferred embodiments specified hereinabove for the first aspect extend to this aspect.

The following Examples illustrate the preparation of the compounds of formula I.

Example 1

Compounds 1 to 126 of formula Ia¹ (see Table 3) were prepared, isolated and purified as follows. Each compound was characterised by a) its HPLC retention time (rt) as determined under the conditions described below, and b) by mass spectroscopy also under the conditions described below.



A series of carboxylic acids of general formula IV (where R^3 is defined in Table 3) (80 μ mol) were each dissolved in a 3.75% solution of triethylamine in dimethylacetamide (400 μ l) and added to a 96 well plate. Carbonyldiimidazole (13mg, 80 μ mol) dissolved in pyridine (212 μ l) was then added into each well, and the plates were left to stand at room temperature for 2 hours. A solution of the product from Preparation 6 (13.5mg, 80 μ mol) dissolved in dimethylacetamide (100 μ l) was then added. The plates were sealed and heated to 70°C in an oven under nitrogen for 18 hours. The plates were removed and allowed to cool to room temperature over 2 hours. The solvent was removed using a GENEVAC (45°C, 0.15mbar) over 5.5 hours. A solution of potassium t-butoxide (268 mg, 240 μ mol) in isopropyl alcohol (0.5ml) was added to each well, and the plates were sealed and transferred to an oven at 110°C under nitrogen for 15 hours. The plates were removed and allowed to cool to room temperature over 2 hours. The solvent was removed using the GENEVAC (45°C, 0.15mbar) over 5.5 hours, and a solution of p-toluenesulfonic acid (30 mg, 160 μ l) in isopropyl alcohol (0.5ml) was added to each well. The plates were left to stand at room temperature for 18 hours and then the solvent was removed using the GENEVAC (45°C, 0.15mbar) over 5.5 hours. The residues were dissolved in dimethylsulfoxide : water (0.5 ml per well, 9:1 v/v) and each compound was purified by preparative high pressure liquid chromatography (HPLC) and the desired compound was characterised by liquid chromatography mass spectroscopy (LC-MS).

Table 1: Preparative HPLC Conditions:


Column	Phenomenex Luna C18, 5 μ m, 150 x 10mm i.d.			
Temperature	Ambient			
Eluent A	0.05% diethylamine (aqueous)			
Eluent B	acetonitrile			
Sample solvent	90% dimethylsulfoxide in water			
Initial pump conditions	A% 95, B% 5, flow 6 ml/min			
Detection	Gilston 119 uv detector – 225nm			
Injection volume	600 μ l			
Gradient Timetable	Time (min)	A%	B%	Flow (ml/min)
	0.0	95	5	6
	0.2	95	5	6
	7.0	5	95	6
	9.0	5	95	6
	9.1	95	5	6
	10.5	95	5	6

Table 2: LC-MS Conditions



Column	Phenomenex Luna C18, 5 μ m, 30 x 4.6mm i.d.				
Temperature	40°C				
Eluent A	0.05% diethylamine (aqueous)				
Eluent B	acetonitrile				
Initial pump conditions	A% 90, B% 10, flow 3ml/min				
Injection volume	5ml				
Detection	products were detected by both ultraviolet and Electron Spray light Scattering (ELSD) uv: start range 210nm, End range 280nm, Range interval 5nm, threshold 0.1mAU, peakwidth 0.4min. ELSD: Sedere Dedex 55, Temperature : 40°C, Gas Flow : 2.3bar				
Gradient Timetable	Time (min)	A%	B%	Flow (ml/min)	Pressure (bar)
	0.0	90	10	3	400
	2.2	5	95	3	400

	2.4	5	95	3	400
	2.5	90	10	3	400
Mass spec conditions	Platform: LC ES+: Cone voltage: 26v, capillary: 4.08kv ES-: Cone voltage: -24v, capillary: -3.58kv Blanket gas: 500l/min Temperature: 130°C				

Table 3



Cmp	R ³	rt (min)	m/z [M+H] ⁺
1	3-chlorobenzyl	1.95	303
2	4-ethoxybenzyl	1.85	313
3	cyclohexylmethyl	1.92	275
4	3-phenoxybenzyl	2.02	361
5	2-chlorobenzyl	1.85	304
6	2-trifluoromethylbenzyl	1.96	337
7	4-chlorobenzyl	1.91	304
8	4-benzyloxybenzyl	2.05	375
9	biphenyl-4-ylmethyl	2.04	345
10	2-(2-chlorophenyl)ethyl	1.93	318
11	2,4,6-trifluorobenzyl	1.89	323
12	3,5-bistrifluoromethylbenzyl	2.07	405
13	3-trifluoromethoxybenzyl	1.97	353
14	4-n-butoxybenzyl	2.08	341
15	3-methylbutyl	1.80	249
16	4-methylsulfanylbzyl	1.83	315
17	ethyl	1.42	207

Cmp	R ³	rt (min)	m/z [M+H] ⁺
18	isobutyl	1.63	235
19	4-methoxybenzyl	1.77	299
20	2,5-dimethylbenzyl	1.93	297
21	benzhydrl	2.07	345
22		1.59	306
23	2-fluoro-3-trifluoromethylbenzyl	1.95	355
24	2,4-difluorobenzyl	1.82	305
25	2,3-difluorobenzyl	1.86	305
26	4-fluorobenzyl	1.80	287
27	2-[(2-imidazol-1-yl)-ethoxy]benzyl	1.44	379
28	5-fluoro-2-trifluoromethyl-benzyl	1.98	355
29	2,6-dichlorobenzyl	1.97	338
30	2-chloro-6-methylbenzyl	2.03	334
31	2-methoxybenzyl	1.76	299
32	4-methylphenoxyethyl	1.92	299
33	3,4-difluorobenzyl	1.83	305
34		1.73	340
35	4-methylbenzyl	1.83	283
36	2-(4-methoxyphenyl)-1-phenylethyl	2.13	389
37	napthalen-1-ylmethyl	2.05	319
38	cyclopentylmethyl	1.77	261
39	2,6-difluorobenzyl	1.83	305
40	3-methylbenzyl	1.84	283
41	2,4-dimethylbenzyl	1.99	297
42	3-fluorobenzyl	1.82	287
43	2,3,6-trifluorobenzyl	1.91	323
44	4-chlorophenoxyethyl	1.97	320
45	4-phenoxybenzyl	2.05	361

Cmp	R ³	rt (min)	m/z [M+H] ⁺
46	2-chloro-6-fluorobenzyl	1.88	322
47	2-benzyloxybenzyl	2.04	375
48	4-methylcyclohexylmethyl	2.02	289
49	1 <i>R</i> -1-phenylpropyl	2.09	297
50	2-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]ethyl	2.05	385
51	n-pentyl	1.83	249
52	2-phenoxybenzyl	2.03	361
53	3,5-dimethylbenzyl	1.97	297
54	4-cyclopentyloxy-3-methoxybenzyl	1.95	383
55	5-naphthalen-2-ylmethyl	1.97	319
56	2,5-dichloro-phenylsulfanylmethyl	2.09	370
57	1 <i>S</i> -1-phenylethyl	1.95	283
58	2-methylbutyl	1.78	249
59	2,5-difluorobenzyl	1.86	305
60	benzyl	1.77	269
61	4-methylpentyl	1.94	263
62	2-cyclohexylethyl	2.07	289
63	2-chloro-4-fluorobenzyl	1.92	321
64	2-(4-trifluoromethylphenyl)ethyl	2.03	351
65	2-ethoxybenzyl	1.88	313
66	phenoxymethyl	1.85	285
67	3-methoxybenzyl	1.76	299
68	3-trifluoromethylbenzyl	1.99	337
69	4-isopropylbenzyl	2.04	311
70	3,5-difluorobenzyl	1.89	305
71	2,5-dimethoxybenzyl	1.80	329
72	2,3-dimethylbenzyl	2.04	313
73	3,4-dichlorobenzyl	2.02	338
74	4-trifluoromethylbenzyl	1.93	337
75	2-methylbenzyl	1.85	283
76	2-fluorobenzyl	1.80	287
77	4-phenylbutyl	1.98	311
78	2-(3,4-dimethoxyphenyl)ethyl	1.69	343


Cmp	R ³	rt (min)	m/z [M+H] ⁺
79	2-(3-methoxyphenyl)ethyl	1.81	313
80	4-ethoxy-3-methoxybenzyl	1.73	343
81	2-(2-methylphenyl)ethyl	1.92	297
82	1-phenoxyethyl	1.86	299
83	2-(3-fluorophenyl)ethyl	1.85	301
84	2,2-diphenylethyl	2.06	359
85	1-methylpropyl	1.73	235
86	3,4-dimethoxybenzyl	1.65	329
87	1-phenoxypropyl	1.97	313
88	(3-methoxyphenoxy)methyl	1.86	315
89	2-(4-fluorophenyl)ethyl	1.85	301
90	(2-isopropyl-5-methylphenoxy)methyl	2.19	341
91	2-(2,5-dimethoxyphenyl)ethyl	1.77	343
92	3-(4,5-dimethoxyphenyl)propyl	1.68	357
93	2,3-dimethoxybenzyl	1.84	329
94	(1,1-diphenyl)ethyl	2.26	359
95	2,3,4-trimethoxybenzyl	1.80	359
96	1-(4-chlorophenoxy)ethyl	1.97	334
97	3,4,5-trimethoxybenzyl	1.69	359
98	(3-trifluoromethyl-phenyl)thiomethyl	2.00	369
99	3-pyridylmethyl	1.28	270
100	(2-chloro-4-fluorophenyl)thiomethyl	1.96	354
101	1-(4-isobutylphenyl)ethyl	1.83	339
102		1.87	297
103	(2-methyl-1-phenyl)propyl	2.13	311
104	2-naphthyloxymethyl	1.98	335
105	3-phenylpropyl	1.87	297
106	2-(4-chlorophenyl)ethyl	1.92	318
107	2-(4-methoxyphenyl)ethyl	1.77	313
108	(cyclopentyl)(phenyl)methyl	2.27	337
109	(2-methoxyphenoxy)methyl	1.82	315

Cmp	R ³	rt (min)	m/z [M+H] ⁺
110	(1-methyl-1-phenyl)ethyl	2.08	297
111	5-methyl-2-phenyl-4-oxazolymethyl	1.95	350
112	1-naphthyloxymethyl	2.06	335
113	2-(3,4-dichlorophenyl)ethyl	2.10	352
114	2,4-dimethoxybenzyl	1.78	329
115	3-(4-methoxyphenyl)propyl	1.86	327
116	isopropyl	1.65	221
117	1-[(3-fluoro-4-phenyl)phenyl]ethyl	2.27	377
118	(1,2-diphenyl)ethyl	2.20	359
119	[2-methyl-4-(phenoxymethyl)]benzyl	2.05	389
120	2-(4-methylphenyl)ethyl	1.94	297
121	(3,4-dimethylphenoxy)methyl	1.98	313
122	1-(4-chlorophenyl)ethyl	2.09	318
123	[1-methyl-1-(4-chlorophenyl)]ethyl	2.23	332
124	3,5-dimethoxybenzyl	1.79	329
125	(2-methyl-1-phenyl)butyl	2.24	325
126	3-phenoxypropyl	1.85	313

Example 2

Compounds 127 to 255 of formula Ia² (see Table 4) were prepared, isolated and purified by largely analogous procedures to Example 1 by reacting the appropriate carboxylic acid IV with the appropriate compound of formula III, except that the GENEVAC conditions were adjusted to 30 deg, 0.15 mbar for 11 hours in all cases. Each compound was characterised by a) its HPLC retention time (rt) as determined under the conditions described above, and b) by mass spectroscopy under the conditions described above.

Table 4

(1a²)


Cmp	R ²	R ³	rt (min)	m/z [M+H] ⁺
127	3-pyridyl	2,4-dichlorobenzyl	1.24	373
128	3-pyridyl	cyclopropylmethyl	0.92	268
129	3-pyridyl	2,6-difluorobenzyl	1.10	340
130	3-pyridyl	(4-methylcyclohexyl)methyl	1.46	324
131	3-pyridyl	3-chlorobenzyl	1.23	339
132	3-pyridyl	2-ethoxybenzyl	1.24	348
133	3-pyridyl	2-phenoxybenzyl	1.46	396
134	3-pyridyl	2,3,5-trifluorobenzyl	1.18	358
135	3-pyridyl	3-fluoro-4-trifluoromethylbenzyl	1.37	390
136	3-pyridyl	5-fluoro-2-trifluoromethylbenzyl	1.29	390
137	3-pyridyl	5-bromo-2-methoxybenzyl	1.30	413
138	3-pyridyl	2-benzyloxybenzyl	1.42	410
139	butyl	2-methylbenzyl	1.44	297
140	butyl	2-methoxybenzyl	1.36	313
141	butyl	2-chlorobenzyl	1.45	318
142	butyl	2-fluorobenzyl	1.34	301
143	butyl	2-chloro-6-fluorobenzyl	1.47	336
144	butyl	2,6-dichlorobenzyl	1.56	352
145	butyl	4-butoxybenzyl	1.72	355
146	butyl	cyclopropylmethyl	1.14	247
147	butyl	2,6-difluorobenzyl	1.38	319
148	butyl	2-ethoxybenzyl	1.48	327
149	butyl	3-benzyloxybenzyl	1.67	389
150	isopropyl	2,4,5-trifluorobenzyl	1.36	323
151	isopropyl	2,4-dichlorobenzyl	1.54	338

Cmp	R ²	R ³	rt (min)	m/z [M+H] ⁺
152	isopropyl	5-bromo-2-methoxybenzyl	1.46	378
153	isopropyl	2,3,6-trichlorobenzyl	1.59	373
154	isopropyl	3-benzyloxybenzyl	1.59	375
155	isopropyl	n-propyl	0.96	221
156	isopropyl	2-trifluoromethoxybenzyl	1.49	353
157	tert-butyl	3-chlorobenzyl	1.61	318
158	tert-butyl	5-bromo-2-methoxybenzyl	1.68	392
159	isobutyl	2,4,5-trifluorobenzyl	1.42	337
160	isobutyl	2-methylbenzyl	1.40	297
161	isobutyl	cyclopentylmethyl	1.39	275
162	isobutyl	isobutyl	1.20	249
163	isobutyl	2-methoxybenzyl	1.32	313
164	isobutyl	2-chlorobenzyl	1.41	318
165	isobutyl	2-fluorobenzyl	1.31	301
166	isobutyl	2-chloro-6-fluorobenzyl	1.44	336
167	isobutyl	2-methylbutyl	1.35	263
168	isobutyl	2-trifluoromethylbenzyl	1.53	351
169	isobutyl	2,4-dichlorobenzyl	1.61	352
170	isobutyl	2,6-dichlorobenzyl	1.54	352
171	isobutyl	4-butoxybenzyl	1.69	355
172	isobutyl	cyclopropylmethyl	1.08	247
173	isobutyl	2,6-difluorobenzyl	1.34	319
174	isobutyl	3-chlorobenzyl	1.44	318
175	isobutyl	2-ethoxybenzyl	1.44	327
176	isobutyl	2-phenoxybenzyl	1.65	375
177	isobutyl	2,3,5-trifluorobenzyl	1.43	337
178	isobutyl	5-bromo-2-methoxybenzyl	1.53	392
179	isobutyl	2-benzyloxybenzyl	1.64	389
180	isobutyl	2-(2-imidazol-1-yl-ethoxy)-benzyl	1.12	393
181	isobutyl	2,3,6-trichlorobenzyl	1.66	387
182	isobutyl	3-benzyloxybenzyl	1.64	389
183	isobutyl	2,3-dihydrobenzofuran-5-ylmethyl	1.25	325
184	cyclopentyl	2,4,5-trifluorobenzyl	1.51	349

Cmp	R ²	R ³	rt (min)	m/z [M+H] ⁺
185	cyclopentyl	2-methylbenzyl	1.52	309
186	cyclopentyl	isobutyl	1.33	261
187	cyclopentyl	2-methoxybenzyl	1.44	325
188	cyclopentyl	2-chlorobenzyl	1.52	330
189	cyclopentyl	2-fluorobenzyl	1.42	313
190	cyclopentyl	2-chloro-6-fluorobenzyl	1.53	347
191	cyclopentyl	2-methylbutyl	1.49	275
192	cyclopentyl	2-trifluoromethylbenzyl	1.62	363
193	cyclopentyl	2,4-dichlorobenzyl	1.70	364
194	cyclopentyl	2,6-dichlorobenzyl	1.61	364
195	cyclopentyl	4-butoxybenzyl	1.80	367
196	cyclopentyl	5-cyclopropylmethyl	1.22	259
197	cyclopentyl	2,6-difluorobenzyl	1.44	331
198	cyclopentyl	2,4,6-trimethoxybenzyl	1.47	385
199	cyclopentyl	3-chlorobenzyl	1.55	330
200	cyclopentyl	2,5-dimethoxybenzyl	1.41	355
201	cyclopentyl	2-ethoxybenzyl	1.55	339
202	cyclopentyl	2-phenoxybenzyl	1.75	387
203	cyclopentyl	3-fluoro-4-trifluoromethylbenzyl	1.67	381
204	cyclopentyl	2-benzyloxybenzyl	1.73	401
205	cyclopentyl	2-(2-imidazol-1-yl-ethoxy)benzyl	1.20	405
206	cyclopentyl	3-benzyloxybenzyl	1.73	401
207	cyclopentyl	n-propyl	1.19	247
208	cyclopentyl	2,3-dihydro-benzofuran-5-ylmethyl	1.35	337
209	isopropyl	2-chlorobenzyl	1.25	304
210	isopropyl	2-chloro-6-fluoro-benzyl	1.25	322
211	isopropyl	2,6-dichlorobenzyl	1.33	338
212	isopropyl	2,5-dimethoxybenzyl	1.15	329
213	3-pyridyl	2-trifluoromethylbenzyl	1.26	372
214	3-pyridyl	2,6-dichlorobenzyl	1.24	373
215	3-pyridyl	2,5-dimethoxybenzyl	1.13	364
216	3-pyridyl	n-propyl	0.89	256
217	3-pyridyl	2,3-dihydrobenzofuran-5-ylmethyl	1.07	346

Cmp	R ²	R ³	rt (min)	m/z [M+H] ⁺
218	3-pyridyl	2,4,6-trimethoxybenzyl	1.20	394
219	butyl	isobutyl	1.24	249
220	butyl	2-trifluoromethylbenzyl	1.55	351
221	butyl	2,4-dichlorobenzyl	1.63	352
222	butyl	2,5-dimethoxybenzyl	1.34	343
223	butyl	2-phenoxybenzyl	1.69	375
224	butyl	2-benzyloxybenzyl	1.67	389
225	butyl	2-[(2-imidazolyl)ethyl]oxy}benzyl	1.15	393
226	butyl	propyl	1.11	235
227	butyl	2,3-dihydrobenzofuran-5-ylmethyl	1.28	325
228	butyl	2,4,6-trimethylbenzyl	1.68	325
229	butyl	2,4,6-trimethoxybenzyl	1.40	373
230	isopropyl	cyclopropylmethyl	0.99	233
231	isopropyl	2,3,5-trifluorobenzyl	1.36	323
232	isopropyl	2,3-dihydrobenzofuran-5-ylmethyl	1.17	311
233	tert-butyl	2-methoxybenzyl	1.51	313
234	tert-butyl	2-chlorobenzyl	1.57	318
235	tert-butyl	2-fluorobenzyl	1.47	301
236	tert-butyl	2-chloro-6-fluorobenzyl	1.55	336
237	tert-butyl	2-trifluoromethylbenzyl	1.64	351
238	tert-butyl	2,4-dichlorobenzyl	1.74	352
239	tert-butyl	2,6-dichlorobenzyl	1.63	352
240	tert-butyl	4-butoxybenzyl	1.88	355
241	tert-butyl	cyclopropylmethyl	1.33	247
242	tert-butyl	2,6-difluorobenzyl	1.47	319
243	tert-butyl	2,5-dimethoxybenzyl	1.49	343
244	tert-butyl	2-ethoxybenzyl	1.65	327
245	tert-butyl	2-phenoxybenzyl	1.82	375
246	tert-butyl	4-CF ₃ -3-fluorobenzyl	1.72	369
247	tert-butyl	2-benzyloxybenzyl	1.81	389
248	tert-butyl	2,3-dihydrobenzofuran-5-ylmethyl	1.44	325
249	tert-butyl	2,4,6-trimethylbenzyl	1.77	325
250	tert-butyl	2,4,6-trimethoxybenzyl	1.54	373

Cmp	R ²	R ³	rt (min)	m/z [M+H] ⁺
251	isobutyl	2,5-dimethoxybenzyl	1.31	343
252	isobutyl	propyl	1.06	235
253	isobutyl	2,4,6-trimethylbenzyl	1.64	325
254	isobutyl	2,4,6-trimethoxybenzyl	1.38	373
255	cyclopentyl	2,4,6-trimethylbenzyl	1.74	337

Example 33-Cyclopentyl-5-(2-trifluoromethoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one (Compound 256)


5

The product from preparation 28 (120mg, 0.303mmol) and potassium tert-butoxide (102mg, 0.909mmol) were suspended in isopropyl alcohol (5ml) and the reaction was heated to reflux under nitrogen for 18h. The reaction mixture was concentrated under reduced pressure and the residue partitioned between ethyl acetate (20ml) and water (20ml). The aqueous phase was removed, acidified to pH2 with 2N HCl, and extracted with ethyl acetate (2x15ml). The combined organic extracts were washed with saturated sodium carbonate solution (3x10ml), dried over MgSO₄, concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with dichloromethane : methanol (95 : 5, by volume) to give the title product (21mg) as an off-white solid, ¹H NMR (400MHz, DMSO-d₆): δ = 7.36-7.41 (2H, m), 7.29-7.36 (2H, m), 3.97-4.03 (2H, brs), 2.39-2.45 (1H, m, partially masked by solvent), 1.82-1.94 (2H, m), 1.66-1.79 (2H, m), 1.58-1.65 (2H, m), 1.49-1.58 (2H, m) ppm; LRMS (electrospray) : m/z [M-H]⁺ 377.


20

Compounds 257 to 261 of formula Ia² were prepared by methods analogous to Example 3 from the starting materials indicated in Table 5 below.


Table 5

(1a²)

Cmp	R ²	R ³	Starting Material	Data
257	isobutyl	2-trifluoromethoxybenzyl	Prep 29	¹ H NMR (400MHz, CDCl ₃): δ 8.64-8.74 (1H, brs), 7.22-7.41 (4H, m, partially masked by solvent), 4.15 (2H, s), 2.79-2.84 (2H, d), 2.13-2.23 (1H, m), 0.92-1.00 (6H, d) ppm; LRMS (electrospray) : m/z [M+H] ⁺ 367, [M-H] ⁺ 365.
258	3-pyridyl	2-trifluoromethoxybenzyl	Prep 30	¹ H NMR (400MHz, CD ₃ OD): δ 9.34 (1H, brs), 8.57-8.61 (1H, d), 8.43-8.48 (1H, m), 7.32-7.47 (5H, m), 4.18 (2H, s) ppm; LRMS (electrospray): m/z [M-H] ⁺ 386.
259	isopropyl	2-(3-chlorobenzyl-oxy)benzyl	Prep 32	¹ H NMR (400MHz, CD ₃ OD): δ 7.2 (m, 6H); 7.0 (d, 1H, J 8.3 Hz); 6.9 (m, 1H); 5.02 (s, 2H); 4.0 (s, 2H); 3.3 (m, 1H); 1.3 (d, 6H, J 7.0 Hz); LCMS: m/z [M+H] ⁺ 409.
260	isopropyl	2-(4-chlorobenzyl-oxy)benzyl	Prep 33	¹ H NMR (400MHz, d6 acetone): δ 7.45 (d, 2H, J 8.3 Hz); 7.35 (d, 2H, J 8.3 Hz); 7.24 (m, 2H); 7.08 (d, 1H, J 7.5 Hz); 6.94 (t, 1H, J 7.5 Hz); 5.02 (s, 2H); 4.08 (s, 2H); 3.26 (m, 1H); 1.35 (d, 6H, J 6.6 Hz); LCMS: m/z [M+H] ⁺ 409.
261	isopropyl	2-benzoyloxy-5-chlorobenzyl	Prep 35	¹ H NMR (400MHz, d6 acetone): δ 7.4-7.24 (m, 7H); 7.1 (d, 1H, J 8.7 Hz); 5.19 (s, 2H); 4.05 (s, 2H); 3.22 (m, 1H); 2.8 (bm, 2H); 1.32 (d, 6H, J 6.6 Hz). LCMS: m/z [M+H] ⁺ 409.

Example 45-(3-Chlorobenzyl)-3-isopropyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Compound 262)

- 5 To a mixture of the product from Preparation 31 (0.2g) in isopropyl alcohol (6 ml) was added potassium tert-butoxide (2.2 g) and stirred at 85°C for 24 hours and then at room temperature for 3 days. The resulting heterogeneous mixture was concentrated *in vacuo*. Water (10 ml) was added to the residue followed by 3 drops of concentrated hydrochloric acid. The resulting precipitate was taken up in
- 10 ethyl acetate (150 ml) and washed with water (x2). The organic extract was dried (MgSO₄) and concentrated to give a solid which was purified by column chromatography using silica gel eluting with a solvent gradient of dichloromethane : methanol (100:0 changing to 99:1 changing to 98:2) to give the title product ; ¹H NMR (400MHz, CD₃OD): δ = 7.39 (1H, s), 7.28 (1H, s), 7.12
- 15 (2H, m), 4.01 (3H, s), 3.96 (2H, s), 3.26 (1H, m), 1.45 (6H, d).

Example 55-(2-Trifluoromethoxybenzyl)-3-phenyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (compound 263)

- 20 Palladium tetrakis triphenylphosphine (22mg, 5 mole %) was added to a nitrogen-purged solution of the product from preparation 36 (164 mg, 0.376 mmol), phenyl boronic acid (69 mg, 0.56 mmol), sodium carbonate (119 mg, 1.13 mmol as a solution in 0.8 ml water) in ethylene glycol dimethyl ether (3 ml). The mixture was
- 25 heated at 83°C for 18 h. On cooling, the mixture was diluted with ethyl acetate/tetrahydrofuran and washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by preparative HPLC

(acetonitrile-water gradient) to afford the title product (15 mg) as a colourless solid. ^1H NMR (400MHz, CD_3OD): δ = 8.2 (bs, 2H); 7.4 (m, 9H); 4.1 (s, 2H); LCMS: m/z $[\text{M}+\text{H}]^+$ 387.

- 5 The following Preparations describe the preparation of certain intermediates used in the preceding Examples.


Preparation 1

5-Methyl-2,4-dioxo-hexanoic acid ethyl ester

- 10 Sodium pellets (3.39g, 148mmol) were dissolved in ethanol (100ml) under nitrogen at room temperature and a solution of diethyloxalate (20ml, 147mmol) in 3-methyl-2-butanone (18.9ml, 177mmol) was added dropwise at room temperature over 30min. The reaction was diluted with ethanol (100ml), heated to 60°C and stirred at this temperature for 2h. After cooling to room temperature
- 15 the reaction was poured onto ice-cold 2N HCl (200ml) and extracted with diethylether (300ml) and ethyl acetate (300ml). The combined organic extracts were dried over MgSO_4 , concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with a solvent gradient of pentane : ethyl acetate (99 : 1 changing to 95 : 5, by volume) to give
- 20 the title product (23.8g) as a yellow oil; ^1H NMR (400MHz, CDCl_3): δ = 14.40-14.80 (1H, brs), 6.40 (1H, s), 4.30-4.39 (2H, quart), 2.60-2.71 (1H, quin), 1.35-1.40 (3H, t), 1.15-1.20 (6H, d) ppm; LRMS (electrospray) : m/z $[\text{M}-\text{H}]^+$ 185.

Preparation 2

- 25 5-Isopropyl-1H-pyrazol-3-carboxylic acid ethyl ester




- Hydrazine hydrate (6.6ml, 134mmol) was added to a solution of the product from Preparation 1 (23.8g, 188mmol) in ethanol (100ml) at room temperature under nitrogen. The reaction was allowed to proceed at room temperature for 18h, and
- 30 the solvent was removed under reduced pressure. The residue was partitioned between dichloromethane (300ml) and water (300ml) and the aqueous phase

was removed. The organic phase was washed with water (2x200ml), dried over MgSO_4 and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with a solvent gradient of pentane : ethyl acetate (4 : 1 changing to 2 : 1, by volume) to give the title

5 product (18.9g) as a white solid; ^1H NMR (400MHz, CDCl_3): δ = 10.80-10.95 (1H, brs), 6.61 (1H, s), 4.33-4.40 (2H, quart), 2.98-3.08 (1H, quin), 1.35-1.41 (3H, t), 1.24-1.32 (6H, d) ppm; LRMS (electrospray) : m/z $[\text{M}-\text{H}]^+$ 181.

Preparation 3


10 5-Isopropyl-1H-pyrazol-3-carboxylic acid



The product from preparation 2 (18.9g, 104mmol) and 1M NaOH solution (260ml, 259mmol) were dissolved in 1,4-dioxan (300ml), the reaction was heated to 50°C under nitrogen and stirred for 3h. The reaction mixture was cooled, adjusted to
15 pH 2 using concentrated hydrochloric acid and the solvent was removed under reduced pressure. The residual solid was azeotroped with toluene (2x30ml), dissolved in ethyl acetate (500ml) and washed with water (200ml). The aqueous phase was removed, extracted with ethyl acetate (2x200ml) and the combined organic extracts were dried over MgSO_4 . The solvent was removed under
20 reduced pressure and the residue was azeotroped with dichloromethane (2x50ml) to give the title product (14.7g) as a white solid; ^1H NMR (400MHz, DMSO- D_6): δ = 12.50-13.30 (2H, brs), 6.42 (1H, s), 2.84-2.94 (1H, quin), 1.15-1.19 (6H, d) ppm; LRMS (electrospray): m/z $[\text{M}-\text{H}]^+$ 153.

Preparation 4

5-Isopropyl-4-nitro-1H-pyrazol-3-carboxylic acid




- 5 The product from preparation 3 (5g, 32.5mmol) was added portionwise to concentrated sulfuric acid (25ml) at room temperature with stirring. The reaction mixture was then heated to 60°C and concentrated nitric acid (70%, 6ml, 90mmol) was added dropwise whilst keeping the temperature at 60°C. The reaction was stirred at 60°C for 3h, cooled to room temperature and then poured
10 onto 50ml of ice with stirring. After 15min the white precipitate was isolated by filtration, washed with water and dried under reduced pressure to give the title product (5.2g) as a white solid; ¹H NMR (400MHz, DMSO-D₆): δ = 13.86-13.93 (1H, brs), 13.50-13.80 (1H, brs), 3.39-3.52 (1H, m), 1.18-1.30 (6H, d) ppm; LRMS (electrospray) : m/z [M-H]⁺ 198.

15

Preparation 5

5-Isopropyl-4-nitro-1H-pyrazol-3-carboxylic acid amide




- 20 Oxalyl chloride (6.8ml, 77.6mmol) was added dropwise to a suspension of the product from preparation 4 (5.15g, 25.9mmol) in dichloromethane (80ml) containing dimethylformamide (0.1ml) under nitrogen at 0°C. The reaction was stirred at 0°C for 1h, allowed to warm to room temperature and stirred for a further 2h. The solvent was removed under reduced pressure, the residue was dissolved in toluene (100ml) and ammonia gas was bubbled into the solution for
25 2h. The reaction was stirred under nitrogen at room temperature for 18h, concentrated under reduced pressure and the residue was dissolved in hot methanol (300ml). The resultant precipitate was filtered and the filtrate was concentrated under reduced pressure. The residue was azeotroped with water

(300ml), concentrated to approximately 80ml under reduced pressure and the precipitate was isolated by filtration. The filtrate was washed with water and dried *in vacuo* to give the title product (3.1g) as an orange solid; ¹H NMR (400MHz, DMSO-D₆): δ = 7.94-7.99 (1H, brs), 7.68-7.72 (1H, brs), 3.45-3.55 (1H, m), 1.24-1.30 (6H, d) ppm; LRMS (electrospray) : m/z [M+Na]⁺ 221, [M-H]⁺ 197.

Preparation 6


4-Amino-5-isopropyl-1H-pyrazol-3-carboxylic acid amide



- 10 The product from preparation 5 (3g, 15.1mmol) and 10% palladium on carbon (500mg) in ethanol (30ml) were stirred under hydrogen (50psi) at room temperature for 18h. The reaction mixture was filtered and the solid was washed with methanol (50ml), dichloromethane (50ml), ethanol (50ml) and ethyl acetate (50ml). The filtrate was concentrated under reduced pressure and the residue
- 15 was purified by flash column chromatography on silica gel eluting with dichloromethane : methanol (9 : 1, by volume) to give the title product (2.6g) as an off-white solid; ¹H NMR (400MHz, DMSO-D₆): δ = 12.20-12.30 (1H, brs), 7.02-7.14 (1H, brs), 6.85-6.95 (1H, brs), 4.30-4.46 (2H, brs), 2.90-3.00 (1H, m), 1.15-1.21 (6H, d) ppm; LRMS (electrospray) : m/z [M-H]⁺ 167, [2M-H]⁺ 335; Anal.
- 20 Found C, 49.86; H, 7.21; N, 33.07. C₇H₁₂N₄O requires C, 49.99; H, 7.19; N, 33.31%.


Preparations 7 to 10 of general formula IIIa were prepared by methods analogous to Preparations 1 to 6 from the starting materials indicated in Table 6.

Table 6




(IIIa)

Prep	R ²	Starting Material
7	butyl	hexan-2-one
8	tert-butyl	tert-butylmethyl ketone
9	isobutyl	isobutyl methyl ketone
10	cyclopentyl	cyclopentylethanone

5 Preparation 114-Amino-5-isopropyl-1-methyl-1H-pyrazole-3-carboxamide


The product from preparation 12 in ethanol was hydrogenated at 50°C and 50 p.s.i. for 2 hours in the presence of 10% palladium on charcoal. The reaction mixture was filtered, concentrated *in vacuo*, and azeotroped with dichloromethane to give the title product as a solid (0.16 g); ¹H NMR (400MHz, CDCl₃): δ = 6.99 (1H, br.s), 6.86 (1H, br.s), 4.41 (2H, br.s), 3.66 (3H, s), 3.02 (1H, m), 1.19 (6H, d).

Preparation 125-Isopropyl-1-methyl-4-nitro-1H-pyrazole-3-carboxamide

- 5 To a mixture of the product from preparation 5 (150 mg) in acetonitrile (6 ml) was added cesium carbonate (107 mg) followed by iodomethane (40 μ l). The mixture was heated at 77 °C overnight. The mixture was concentrated *in vacuo* and the residue taken up in ethyl acetate (200 ml) and washed with brine. The organic extracts were dried (MgSO₄), the solvent was removed and the residue
- 10 purified by chromatography using silica gel eluting with pentane : ethyl acetate (100:0 to 15:1 to 1:1); ¹H NMR (400MHz, CDCl₃): δ = 6.50 (1H, br.s), 5.65 (1H, br.s), 3.89 (3H, s), 3.43 (1H, m), 1.36 (6H, d).

Preparation 13


15 4-Amino-5-(3-pyridyl)-1H-pyrazole-3-carboxamide



- A solution of the product from preparation 14 (1 g) in 0.88M ammonia (100 ml) were heated at 100°C in a bomb overnight. The mixture was concentrated *in vacuo* and the residue was purified by chromatography using silica gel eluting
- 20 with dichloromethane : methanol (9:1) to give the title product (709 mg).

Preparation 14


Ethyl 4-amino-5-(3-pyridyl)-1H-pyrazole-3-carboxylate




To an ice-cooled solution of sodium ethoxide (34 ml, 21% w/w) in ethanol (50 ml)
5 was added 3-(cyanomethyl)pyridine (10 ml) dropwise over 30 minutes. The
reaction mixture was stirred for 30 minutes at 0°C and diazoacetic acid (9.9 ml)
was added dropwise over 15 minutes. The reaction mixture was allowed to warm
to room temperature and stirred overnight. Water was added and the solution
was neutralised with carbon dioxide. On extracting the mixture with ethyl acetate
10 and dichloromethane (approx 1000 ml), a solid precipitated. Filtration of the solid
gave the title product (13.6 g).

Preparation 15

4-Amino-1H-pyrazol-3-carboxylic acid amide




The title product was prepared by an analogous method to Preparation 6 starting
from the product of Preparation 16.

Preparation 164-Nitro-1H-pyrazol-3-carboxylic acid amide

5


The title product was prepared by an analogous method to Preparation 5 starting from 4-nitro-1H-pyrazol-3-carboxylic acid (Sigma-Aldrich Chemical Co.)

Preparation 1710 (3-Benzyloxy-phenyl)-acetic acid benzyl ester

3-Hydroxy-phenyl-acetic acid (15.3g, 101mmol), benzyl bromide (36.2g, 202mmol) and potassium carbonate (29.2g, 202mmol) were suspended in dimethylformamide (300ml) and the reaction was heated to reflux under nitrogen for 44h. The reaction mixture was cooled, filtered and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (200ml) and water (200ml), and the aqueous phase was extracted with ethyl acetate (2x200ml). The combined organic extracts were washed with brine (200ml), dried over Na₂SO₄ and the solvent was removed under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with pentane : ethyl acetate (95 : 5, by volume) to give the title product (10.7g) as a white solid.

Preparation 18


(3-Benzyloxy-phenyl)-acetic acid



1N Sodium hydroxide solution (35ml, 35mmol) was added to a solution of the product from preparation 17 (5.3g, 16mmol) in methanol (350ml) at room temperature under nitrogen. The reaction was heated to reflux for 2h, and the solvent was removed under reduced pressure. The residue was dissolved in water (500ml) and extracted with ether (3x350ml). The aqueous phase was acidified to pH 1 with concentrated hydrochloric acid and the resultant precipitate was isolated by filtration and dried under vacuum to give the title product (3.08g) as a white solid, m.p. 127-129°C; ¹H NMR (400MHz, CDCl₃): δ = 7.26-7.43 (5H, m), 7.20-7.26 (1H, m, partially masked by solvent), 6.84-6.96 (3H, m + s), 5.04 (2H, s), 3.62 (2H, s) ppm; LRMS (electrospray) : m/z [M-H]⁺ 241; Anal. Found C, 74.21; H, 5.82. C₁₅H₁₄O requires C, 74.36; H, 5.82%.

Preparation 19

(4-Hydroxy-3-methoxy-phenyl)-acetic acid methyl ester




Concentrated sulfuric acid (12ml) was added to a solution of (4-hydroxy-3-methoxy-phenyl)-acetic acid (22.5g, 123mmol) in methanol (450ml) at room temperature, and the reaction was heated to 90°C for 2.45h. The reaction was then cooled to room temperature and stirred for 18h, and the solvent was removed under reduced pressure. The residue was suspended in ice water (300ml) and extracted with diethylether (2x300ml). The combined organic extracts were washed with sat. sodium bicarbonate solution (2x100ml), brine

(100ml), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with a solvent gradient of cyclohexane : ethyl acetate (80 : 20 changing to 70 : 30, 60 : 40 and finally 1 : 1, by volume) to give the title product (23g) as a yellow oil; ^1H NMR (400MHz, CDCl_3): δ = 6.82-6.85 (1H, d), 6.80 (1H, s), 6.76-6.79 (1H, d), 5.49 (1H, s), 3.86 (3H, s), 3.66 (3H, s), 3.53 (2H, s) ppm; LRMS (electrospray) : m/z $[\text{M}+\text{Na}]^+$ 219.

Preparation 20


10 (4-Cyclopentyloxy-3-methoxy-phenyl)-acetic acid methyl ester



Cyclopentanol (7.7ml, 85mmol) and triphenylphosphine (28g, 107mmol) were added to a solution of the product from preparation 19 (14g, 71mmol) in tetrahydrofuran (280ml) under nitrogen at 0°C. Diethylazodicarboxylate (15.7ml, 100mmol) was then added dropwise and the reaction was allowed to warm to room temperature and stirred for 44h. The solvent was removed under reduced pressure, pentane (200ml) was added and the suspension was filtered. The filtrate was concentrated under reduced pressure and purified by flash column chromatography on silica gel eluting with a solvent gradient of cyclohexane : ethyl acetate (90 : 10 changing to 85 : 15, by volume) to give the title product (12.4g) as a colourless oil; ^1H NMR (400MHz, CD_3OD): δ = 6.79-6.85 (2H, m), 6.73-6.79 (1H, d), 4.73-4.79 (1H, brs), 3.79 (3H, s), 3.64 (3H, s), 3.53 (2H, s), 1.74-1.89 (6H, m), 1.56-1.67 (2H, m) ppm; LRMS (electrospray) : m/z $[\text{M}+\text{Na}]^+$ 287; Anal. Found C, 68.01; H, 7.74. $\text{C}_{15}\text{H}_{20}\text{O}_4$ requires C, 68.16; H, 7.63%.

Preparation 21

(4-Cyclopentyloxy-3-methoxy-phenyl)-acetic acid



Sodium hydroxide (4.75g, 119mmol) was added to a solution of the product from preparation 20 (12.4g, 46.9mmol) in methanol (100ml) / water (100ml) and the reaction was stirred at room temperature for 3.5h. The methanol was removed under reduced pressure and the aqueous phase was washed with diethylether (100ml) then acidified to pH2 using concentrated hydrochloric acid. This was then extracted with ethyl acetate (2x200ml) and the combined organic extracts were washed with brine (100ml), dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (11.1g) as a white solid; ¹H NMR (400MHz, CD₃OD): δ = 6.87 (1H, s), 6.81-6.86 (1H, d), 6.76-6.80 (1H, d), 4.75-4.79 (1H, brs), 3.78 (3H, s), 3.49 (2H, s), 1.71-1.89 (6H, m), 1.56-1.64 (2H, m) ppm; LRMS (electrospray): m/z [M-H]⁺ 249, [2M-H]⁺ 499; Anal. Found C, 67.15; H, 7.25. C₁₄H₁₈O₄ requires C, 67.18; H, 7.25%.

Preparation 22

2,4-Dimethylphenyl-acetic acid

2,4-Dimethylbenzylcyanide (70g, 0.48mol) was mixed with water (134ml) and concentrated sulfuric acid (106ml, 1.98mol) was added slowly. The reaction was heated to reflux for 3h, then cooled to room temperature over 18h. The mixture was poured onto crushed ice (500ml), stirred for 1h and the resulting precipitate was isolated by filtration. After washing with water the solid was dissolved in 1.2M sodium hydroxide solution (500ml), extracted with dichloromethane (2x250ml) and the aqueous phase was treated with decolourising carbon (2g) at reflux for 10min and filtered hot through hyflo supercel. The filtrate was then acidified with concentrated hydrochloric acid and the resulting precipitate was isolated by filtration, washed with water and dried under vacuum to give the title

product (52.6g) as a white solid; ^1H NMR (250MHz, $\text{CD}_3\text{OD}/\text{D}_2\text{O}$): $\delta = 6.88\text{-}7.03$ (3H, m), 3.48-3.68 (2H, s), 2.23 (6H, s) ppm.

Preparation 23


5 Benzene sulfonic acid 2-chloro-ethyl ester

2-Chloroethanol (1168g, 14.5 mol) and benzene sulfonyl chloride (2780g, 15.7 mol) were stirred together at -5°C and pyridine (2158g, 27.2mol) was added over a 3h period, maintaining the temperature below 0°C . The reaction was stirred for a further 3h at $-5\text{-}0^\circ\text{C}$ and was then allowed to warm to room temperature over
10 18h. After pouring into a mixture of ice (10l) and water (10l) the reaction was stirred for 15min, extracted with ether (10l) and the organic phase was washed with 5N HCl (2x2l) and water (2x4l). It was then dried over MgSO_4 and concentrated under reduced pressure to give the title product (1921g) as an orange oil; ^1H NMR (250MHz, CDCl_3): $\delta = 7.78\text{-}8.02$ (2H, m), 7.58-7.78 (3H, m),
15 4.20-4.45 (2H, t), 3.60-3.81 (2H, t) ppm.


Preparation 24

2-Hydroxy-phenyl-acetic acid ethyl ester

2-Hydroxy-phenyl-acetic acid (30.4g, 0.2mol) was dissolved in chloroform
20 (200ml) and thionyl chloride (50ml, 0.2mol) was added. The reaction was gently refluxed for 2h, upon which the mixture was concentrated under reduced pressure. The residue was slowly poured into ethanol (200ml) maintaining a temperature of $10\text{-}20^\circ\text{C}$. The solvent was removed under reduced pressure and the residue was purified by thermal distillation to give the title product (31.6g) as
25 a yellow oil, b.p. $146\text{-}150^\circ\text{C}$; ν_{max} (thin film) 1710cm^{-1} (C=O, ester).

Preparation 25[2-(2-Chloro-ethoxy)-phenyl]-acetic acid ethyl ester

50% Sodium hydride in mineral oil (8.11g, 169mmol) was added portionwise to a solution of the product from preparation 24 (30.4g, 169mmol) in dimethylformamide (100ml). After the initial effervescence had ended the reaction was heated to 100°C for 10min and was cooled to room temperature. A solution of benzene sulfonic acid 2-chloro-ethyl ester (37.2g, 169mmol) in dimethylformamide (5ml) was then added and the reaction was heated to 100°C for 1h, and allowed to cool to room temperature over 18h. The reaction mixture was partitioned between diethylether (300ml) and water (300ml) and the organic phase was removed and washed with water (100ml), dried over MgSO₄ and the solvent was removed under reduced pressure. The residue was purified by thermal distillation to give the title product (22.0g) as a pale yellow oil; b.p. 170-180°C; ν_{\max} (thin film) 1735cm⁻¹ (C=O, ester); no O-H stretch; Anal. Found C, 59.35; H, 6.29. C₁₂H₁₅ClO₃ requires C, 59.38; H, 6.23%.


Preparation 26[2-(2-Imidazol-1-yl-ethoxy)-phenyl]-acetic acid ethyl ester

To a solution of imidazole (4.5 g) in dry dimethylformamide (80 ml) at room temperature was added sodium hydride (3.17 g of a 50% suspension). The mixture was heated at 100°C for 10 mins then cooled to room temperature. The product from preparation 25 (16 g) was added in dry dimethylformamide (5 ml) and then heated to 100°C for 4.5 hours. The reaction mixture was cooled and water was added. The mixture was extracted with chloroform, the combined extracts dried (MgSO₄) and the solvent removed to give the crude product. The

crude product was converted to the hydrochloride salt and purified by recrystallisation from isopropyl alcohol/ethyl acetate to give the title product as its hydrochloride salt, m.p. 129.5-130.5 °C.

5 Preparation 27


[2-(2-Imidazol-1-yl-ethoxy)-phenyl]-acetic acid



The product from Preparation 26 (3.5g, 113mmol) was stirred in 50% aqueous hydrochloric acid (20ml) at 100°C for 6h. After cooling to room temperature the solvent was removed under reduced pressure and the residue was recrystallised from isopropyl alcohol to give the title product (2.73g) as a white solid; m.p. 146-147°C; ν_{\max} (thin film) 3410 (O-H), 1722cm⁻¹ (C=O, acid); Anal. Found C, 54.89; H, 5.25; N, 9.80. C₁₃H₁₄N₂O₃. 1 mol HCl requires C, 55.22; H, 5.35; N, 9.91%.

15 Preparation 28

5-Cyclopentyl-4-[2-(2-trifluoromethoxy-phenyl)-acetylamino]-1H-pyrazole-3-carboxylic acid amide




Carbonyldiimidazole (84mg, 0.515mmol) was added to a solution of 2-trifluoromethoxyphenyl acetic acid (113mg, 0.515mmol) in tetrahydrofuran (4ml) under nitrogen at room temperature, and the mixture was stirred for 3h. The product from preparation 10 (100mg, 0.515mmol) was then added and the reaction was stirred for 18h. The reaction mixture was diluted with water (20ml), acidified to pH2 with 2N HCl and extracted with ethyl acetate (2x20ml). The combined organic extracts were dried over MgSO₄ and concentrated under

reduced pressure to give the title product (120mg) as an off-white solid; LRMS (electrospray): m/z $[M+H]^+$ 397, $[M-H]^+$ 395.


- Preparations 29 to 34 of general formula II were prepared by analogous
5 procedures to Preparation 28 from the starting materials indicated in Table 7.

Table 7



(II)


Prep	R ¹	R ²	R ³	Starting pyrazole	Starting acid
29	H	isobutyl	2-trifluoromethoxybenzyl	Prep 9	2-trifluoromethoxy phenyl acetic acid
30	H	3-pyridyl	2-trifluoromethoxybenzyl	Prep 13	2-trifluoromethoxy phenyl acetic acid
31	Me	isopropyl	3-chlorobenzyl	Prep 11	3-chlorophenyl acetic acid
32	H	isopropyl	2-(3-chlorobenzoyloxy)-benzyl	Prep 6	2-(3-chlorobenzoyloxy)phenyl acetic acid
33	H	isopropyl	2-(4-chlorobenzoyloxy)-benzyl	Prep 6	2-(4-chlorobenzoyloxy)phenyl acetic acid
34	H	H	2-trifluoromethoxybenzyl	Prep 15	2-trifluoromethoxyphenyl acetic acid

Preparation 354-[[2-Benzyloxy-5-chloro-phenyl]acetyl]amino]-5-isopropyl-1H-pyrazole-3-carboxamide

5

1-Propylphosphonic acid cyclic anhydride (0.39 ml of a 50 % solution in ethyl acetate, 0.57mmol) was added to a solution of 2-benzyloxy-5-chlorophenyl acetic acid (132mg, 0.475mmol), the product from preparation 6 (80mg, 0.475mmol) and triethyl amine (0.132 ml, 0.95 mmol) in dimethylformamide (4ml) under nitrogen at room temperature and the reaction was stirred for 18h. The reaction mixture was diluted with brine (20 ml) and extracted with ethyl acetate (2x20ml). The combined organic extracts were dried over MgSO₄ and concentrated under reduced pressure to give the title product (191mg) as an off-white solid; LCMS: m/z 427 [M+H]⁺.

15

Preparation 365-(2-Trifluoromethoxybenzyl)-3-iodo-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one


N-Iodosuccinimide (326 mg, 1.45 mmol) was added to a solution of the product from preparation 37 (300 mg, 0.967 mmol) in dry dimethylformamide (5 ml) at room temperature. The mixture was heated at 55°C for 18 h, cooled and concentrated *in vacuo*. The residue was dissolved in ethyl acetate/tetrahydrofuran and washed with water and brine, dried (MgSO₄), filtered and concentrated. The crude product was purified by flash chromatography (1→2% MeOH/CH₂Cl₂) to afford the title product (169 mg) as an off-white solid;

25

^1H NMR (400 MHz, CD_3OD) δ 7.35 (m, 4H); 4.1 (s, 2H); LCMS: m/z 437 $[\text{M}+\text{H}]^+$.

Preparation 37

5 5-(2-trifluoromethoxy-benzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one



The title product was prepared by an analogous process to that of Example 3 starting from the product of preparation 34; MS: m/z $[\text{M}+\text{H}]^+$ 311.

Assay

The ability of the compounds of the invention to inhibit the PDE9 enzyme was determined using the following *in vitro* assay. The assay used purified recombinant human PDE9.

The assay uses $[\text{}^3\text{H}]\text{cGMP}$ which is hydrolysed by the PDE9 enzyme to the 5'-nucleotide $[\text{}^3\text{H}]\text{GMP}$. The $[\text{}^3\text{H}]\text{GMP}$ binds to yttrium silicate scintillation proximity assay (SPA) beads, and detected by scintillation counting. Inhibition of activity is determined relative to the activity of uninhibited controls.

Materials/reagents

- Recombinant human PDE-9 enzyme (Flag-tagged) was obtained by expression in a baculovirus/*Sf9* cell system and purified by anti-FLAG monoclonal antibody affinity chromatography (D A Fisher, J F Smith, J S Pillar, S H Denis, J B Cheng (1998), *J. Biol. Chem.*, 273: 15559-15564).
- Phosphodiesterase Scintillation Proximity Assay (SPA) beads (Yttrium Silicate) were obtained from Amersham Biotech.
- $[\text{}^3\text{H}]\text{Guanosine 3',5'-Cyclic Phosphate}$ ($[\text{}^3\text{H}]\text{-cGMP}$), Ammonium Salt was obtained from Amersham Biotech.

Preparation of Assay Buffers and Solutions

- Buffer A was prepared containing Tris.HCl (20 mM), $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ (5 mM) in water. The resulting solution was used at 30°C and had a pH of pH=7.4.
- Buffer B was prepared containing Bovine Serum Albumin (2 mg/ml) (BSA) in Buffer A. It was prepared fresh and filter sterilised.
- PDE9 enzyme solution was prepared in Buffer B (dilution factor determined such that no more than 30% breakdown of substrate occurred, but typically 1:35,000).
- cGMP substrate was prepared from a 50nM stock of guanosine 3':5'-cyclic monophosphate (cGMP) prepared to give final assay concentration of 25nM (to prepare 5ml based on specific activity of labelled substrate of 16.0Ci/mmol; 1mCi/ml, add 4 μl [^3H]cGMP to 4.996ml Buffer A).
- SPA beads were prepared by creating a suspension of beads in water (20 mg/ml) (28ml per pack) containing 3mM cold cGMP to effectively quench the reaction.

Preparation of Compounds

The compounds of the invention were diluted by a factor of 50 (i.e. 2 μl in 100 μl) when constituted in the final assay mix. Compound stock was prepared at 4mM in DMSO. Dilute 1/8 with DMSO to give 500 μM solutions.

A 4mM stock of standard inhibitor was prepared in DMSO. The standard inhibitor chosen was 5-(3-bromobenzyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one. The solution was further diluted with DMSO to give a 500 μM solution.

For 10-point $\frac{1}{2}$ log dilution, 200 μl of compound and standard solutions were dispensed into a 96-well V-bottom plate and the compounds further diluted with DMSO in steps of 1:3.16. Following serial dilution, 2 μl of compound dilutions were dispensed in duplicate into microtitre plates with 2 μl DMSO added to controls as shown below.

<u>Control</u>	<u>Blank</u>	<u>Test compound dilution</u>
2µl DMSO	2µl DMSO	2µl Test compound
25µl Buffer A	25µl Buffer A	25µl Buffer A
25µl Enzyme	25µl Buffer B	25µl Enzyme
50µl Substrate	50µl Substrate	50µl Substrate
50µl SPA to stop	50µl SPA to stop	50µl SPA to stop

Assay procedure

To the microtitre plates containing solutions of compounds of the invention (2µl) was added Buffer A (25µl) to all wells. Buffer B (25µl) was added to blank wells.

5 Enzyme solution (25µl) was added all wells except blanks. Substrate solution (50µl) was added to each well. The plates were sealed and incubated for 15 minutes on a plate-shaker at 30°C. SPA bead solution (50µl) was added (containing excess cGMP) to each well to stop the reaction (Note: yttrium silicate beads are dense and require constant agitation whilst being added to each

10 plate). The plates were shaken for 15 minutes to allow the beads to bind the GMP product and then allowed to settle for 30 minutes.

The plates were then analysed using a scintillation counter (such as the NXT TopCount)TM.

15 For each compound the percentage inhibition was calculated by the following equation:

$$(mean\ maximum - compound\ value) / (mean\ maximum - mean\ minimum) \times 100$$

20 IC50 values were determined from sigmoid dose response curves of enzyme activity vs. compound concentration. The IC₅₀ of the standard was expected to fall in the range 30 – 50nM.

25 The ability of the compounds to inhibit the PDE1 enzyme was determined by an assay procedure broadly analogous to that described above for PDE9. The differences are as follows: i) human PDE1 enzyme was isolated from human

ventricle homogenate by chromatographic separation of a high speed centrifugation supernatant fraction; ii) the cGMP substrate (1 μ M) was prepared by combining 0.436 ml of a 10 μ M stock of unlabelled guanosine 3':5'-cyclic monophosphate (cGMP) with 10 μ M [3H]cGMP (15.6Ci/mmol) and 4.554 ml

5 Buffer A; the final assay concentration of cGMP in the assay being 0.5 μ M, iii) the PDE1 inhibitor used as a standard was 5-[4-(N,N-diethylamino)benzyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, and iv) during the procedure the plates were incubated for 30 minutes.

10 The compounds of the invention were tested using the above assays and found to inhibit the PDE9 enzyme.

Compounds 1-21, 23-31, 33-77, 118, 127-208, 213, 214, 224 and 256-263 were found to have a greater than 40% inhibition against PDE9 at a concentration of


15 1 μ M .

In particular, compound 52 was found to have an IC₅₀ against PDE9 of 126 nM; compound 204 was found to have an IC₅₀ against PDE9 of 143 nM; and compound 258 was found to have an IC₅₀ against PDE9 of 141 nM. Compounds

20 52, 204 and 258 were all greater than 10 fold selective for PDE9 over PDE1.

Claims

- 1 A compound of formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof



5 wherein

R^1 is H or C_{1-6} alkyl, wherein R^1 is attached to either N^1 or N^2 ;

R^2 is C_{1-6} alkyl optionally substituted by hydroxy or alkoxy; C_{3-7} cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het^1 or Ar^1 ;

10

R^3 is C_{1-6} alkyl optionally substituted by 1 or 2 groups independently selected from: Ar^2 ; C_{3-7} cycloalkyl optionally substituted by C_{1-6} alkyl; OAr^2 ; SAr^2 ; $NHC(O)C_{1-6}$ alkyl; het^2 ; xanthene; and naphthalene; wherein Ar^1 and Ar^2 are independently groups of formula



15

wherein R^4 , R^5 and R^6 are independently selected from: hydrogen, halo, phenoxy, phenyl, CF_3 , OCF_3 , R^7 , SR^7 and OR^7 , wherein R^7 is C_{1-6} alkyl optionally substituted by het^3 or by a phenyl group optionally substituted by 1, 2 or 3 groups independently selected from halo, CF_3 , OCF_3 , C_{1-6} alkyl and C_{1-6} alkoxy; or wherein R^4 and R^5 combine to form a 3 or 4 atom link, wherein said link may incorporate one or two heteroatoms independently selected from O, S and N; and wherein het^1 , het^2 and het^3 , which may be the same or different, are aromatic 5-6 membered heterocycles containing 1, 2 or 3 heteroatoms, independently selected from O, S and N, said heterocycle optionally substituted by 1, 2 or 3 substituents, independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, halo and phenyl

20

25


optionally substituted by 1, 2 or 3 groups independently selected from halo and C₁₋₆ alkyl;

with the provisos that when

a) R¹ is attached to N¹, R¹ is C₁₋₃ alkyl and R² is propyl then R³ is not methyl substituted by Ar¹, and

b) R¹ is attached to N¹, R¹ is C₁₋₆ alkyl and R² is methyl then R³ is not C₁₋₄alkyl substituted by Ar¹.

2 A compound according to claim 1 wherein the compound is of formula Ia,
10 a pharmaceutically acceptable salt, solvate or prodrug thereof




wherein

R¹ is H or C₁₋₆ alkyl;

R² is C₁₋₆ alkyl optionally substituted by hydroxy or alkoxy; C₃₋₇ cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het¹ or Ar¹;

R³ is C₁₋₆ alkyl optionally substituted by 1 or 2 groups independently selected from: Ar²; C₃₋₇-cycloalkyl optionally substituted by C₁₋₆alkyl; OAr²; SAR²; NHC(O)C₁₋₆ alkyl; het²; xanthene; and naphthalene;

wherein Ar¹ and Ar² are independently groups of formula



wherein R⁴, R⁵ and R⁶ are independently selected from: hydrogen, halo, phenoxy, phenyl, CF₃, OCF₃, R⁷, SR⁷ and OR⁷, wherein R⁷ is C₁₋₆ alkyl optionally substituted by het³ or by a phenyl group optionally substituted by 1, 2 or 3 groups independently selected from halo, CF₃, OCF₃, C₁₋₆ alkyl and C₁₋₆alkoxy; or wherein R⁴ and R⁵ combine

to form a 3 or 4 atom link, wherein said link may incorporate one or two heteroatoms independently selected from O, S and N; and wherein het^1 , het^2 and het^3 , which may be the same or different, are aromatic 5-6 membered heterocycles containing 1, 2 or 3 heteroatoms, independently selected from O, S and N, said heterocycle optionally substituted by 1, 2 or 3 substituents, independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, halo and phenyl optionally substituted by 1, 2 or 3 groups independently selected from halo and C_{1-6} alkyl;

with the provisos that when

- a) R^1 is C_{1-3} alkyl and R^2 is propyl then R^3 is not methyl substituted by Ar^1 , and
- b) R^1 is C_{1-6} alkyl and R^2 is methyl then R^3 is not C_{1-4} alkyl substituted by Ar^1 .

15

3 A compound according to any preceding claim wherein R^1 is hydrogen or CH_3 .

20 4 A compound according to any preceding claim wherein R^1 is hydrogen.

5 A compound according to any preceding claim wherein R^2 is C_{3-4} alkyl, cyclopentyl or pyridyl.

25 6 A compound according to any preceding claim wherein R^2 is 3-pyridyl.

7 A compound according to any preceding claim wherein R^3 is C_{1-3} alkyl optionally substituted by 1 or 2 groups independently selected from: Ar^2 ; C_{3-7} cycloalkyl optionally substituted by C_{1-6} alkyl; and het^2 .

30 8 A compound according to any preceding claim wherein R^3 is C_{1-3} alkyl optionally substituted by Ar^2 .

- 9 A compound according to any preceding claim wherein R³ is methyl substituted by Ar².
- 10 A compound according to any preceding claim wherein R⁴, R⁵ and R⁶ are
5 independently selected from: hydrogen, halo, phenoxy, phenyl, CF₃, OCF₃, R⁷, SR⁷, and OR⁷, wherein R⁷ is C₁₋₆alkyl optionally substituted by a het³ group or by a phenyl group optionally substituted by 1, 2 or 3 groups independently selected from halo, CF₃, OCF₃, C₁₋₆ alkyl and C₁₋₆alkoxy; or
10 wherein R⁴ and R⁵ combine to form a 3 atom link wherein said link contains an oxygen atom.
- 11 A compound according to any preceding claim wherein R⁴, R⁵ and R⁶ are independently selected from hydrogen, halo, CF₃, OCF₃, phenoxy, and
15 OC₁₋₆ alkyl optionally substituted by phenyl optionally substituted by halo, CF₃, OCF₃ or C₁₋₆ alkyl.
- 12 A compound according to any preceding claim wherein R⁴, R⁵ and R⁶ are independently selected from hydrogen, chloro, OCF₃, CF₃, phenoxy and
20 OC₁₋₆ alkyl substituted by phenyl.
- 13 A compound according to any preceding claim wherein R⁴, R⁵ and R⁶ are independently selected from hydrogen, chloro, OCF₃ and OC₁₋₃ alkyl substituted by phenyl.
- 25 14 A compound according to any one of claims 1 to 7 wherein het² is an aromatic 5-6 membered heterocycle containing 1 or 2 nitrogen atoms optionally containing a further heteroatom, said heterocycle being optionally substituted by 1, 2 or 3 substituents, each independently
30 selected from C₁₋₆ alkyl, halo and phenyl optionally substituted by 1, 2 or 3 groups independently selected from halo and C₁₋₆ alkyl.
- 15 A compound according to claim 14 wherein het² is an aromatic 5-membered heterocycle containing 1 or 2 nitrogen atoms (optionally

containing a further heteroatom) said heterocycle being optionally substituted by 1 substituent selected from C₁₋₆ alkyl, halo and phenyl optionally substituted by 1, 2 or 3 groups independently selected from halo and C₁₋₆ alkyl.

5

16 A compound according to claim 15 wherein het² is an aromatic 5 membered heterocycle containing 1 or 2 nitrogen atoms (optionally containing a further heteroatom) and optionally substituted by phenyl optionally substituted by halo.

10

17 A compound according to claim 16 wherein het² is imidazolyl or oxadiazolyl.

15

18 A compound according to claim 1 wherein the compound is:
5-(3-chlorobenzyl)-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidine-7-one (compound 1);
3-isopropyl-5-(2-phenoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidine-7-one (compound 52);
3-(3-pyridinyl)-5-(2-benzyloxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidine-7-one (compound 138);
3-isopropyl-5-(2-trifluoromethoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidine-7-one (compound 156);
3-cyclopentyl-5-(2-benzyloxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidine-7-one (compound 204);
3-(3-pyridinyl)-5-(2-trifluoromethylbenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidine-7-one (compound 215);
3-cyclopentyl-5-(2-trifluoromethoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one (compound 258); and
3-(3-pyridinyl)-5-(2-trifluoromethoxybenzyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one (compound 260).

30

19 The use of a compound defined in any preceding claim, a pharmaceutically acceptable salt or solvate thereof, in the manufacture of


a medicament for treating or preventing a cardiovascular disorder, disease or condition.

20 The use according to claim 19, a pharmaceutically acceptable salt or
5 solvate thereof, wherein the disorder, disease or condition is systemic hypertension.

21 A compound defined in any one of claims 1 to 18, a pharmaceutically
10 acceptable salt or solvate thereof, for use as a medicament.

22 A pharmaceutical composition comprising a compound defined in any one
of claims 1 to 18, a pharmaceutically acceptable salt or solvate thereof,
together with a pharmaceutically acceptable excipient, diluent or carrier.

15 23 A process for preparing a compound of formula I as defined in any one of
claims 1 to 18 comprising reacting a compound of formula II with a
suitable reagent to effect cyclisation.



(II)

20 24 The use of a PDE9 inhibitor in the manufacture of a medicament for
treating or preventing a cardiovascular disorder, disease or condition.

25 25 The use according to claim 24 wherein the PDE9 inhibitor has a greater
than 40% inhibition against PDE9 at a concentration of 1 micromolar.

25 26 The use according to claim 25 wherein the PDE9 has a selectivity for
PDE9 over PDE1 of greater than 10.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/04385

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/505 A61P9/00 A61P15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 911 333 A (PFIZER LTD ;PFIZER (US)) 28 April 1999 (1999-04-28) the whole document	1-26
X	EP 1 097 706 A (PFIZER LTD ;PFIZER (US)) 9 May 2001 (2001-05-09) page 31 -page 33	1-26
P,X	WO 02 062799 A (REDDY RESEARCH FOUNDATION) 15 August 2002 (2002-08-15) * preparation 10 * claim 1	1-26
X	EP 0 201 188 A (WARNER LAMBERT CO) 17 December 1986 (1986-12-17) claim 1	1-26

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

11 December 2002

Date of mailing of the international search report

13/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Baston, E

INTERNATIONAL SEARCH REPORT

ernational Application No

PCT/IB 02/04385

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 939 161 A (RATAJCZYK JAMES DANIEL ET AL) 17 February 1976 (1976-02-17) claim 1; example 16 -----	1-26
X	HAMILTON H W ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF PYRAZOLOU4,3-D PYRIMIDIN-7-ONES AS ADENOSINE RECEPTOR ANTAGONISTS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 30, no. 1, 1987, pages 91-96, XP002040681 ISSN: 0022-2623 example 5B -----	1
X	DEWALD, H.A. ET AL: "Synthesis and Potential Antipsychotic Activity of 1H-Imidazo'1,2-c!pyrazolo'3,4-e! pyrimidines" JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, 1988, pages 454-461, XP002224492 example 2G -----	1
A	WO 00 12504 A (NIEWOEHNER ULRICH ;HANING HELMUT (DE); BAYER AG (DE); BISCHOFF ERW) 9 March 2000 (2000-03-09) page 20 -page 23; claim 1 -----	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/04385**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 24-26
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 24-26

Present claims 24-26 relate to uses of compounds defined by reference to a desirable property, namely inhibition of PDE9.

These claims cover the use of all compounds revealing inhibition of PDE9 as characteristic feature, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of claims 24-26 which relate to compounds according to formula (I).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/04385

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0911333	A	28-04-1999	AT 215954 T	15-04-2002
			BR 9804214 A	14-12-1999
			CA 2251453 A1	24-04-1999
			DE 69804743 D1	16-05-2002
			DE 69804743 T2	08-08-2002
			DK 911333 T3	01-07-2002
			EP 0911333 A1	28-04-1999
			ES 2175624 T3	16-11-2002
			JP 3270830 B2	02-04-2002
			JP 11217383 A	10-08-1999
			PT 911333 T	30-08-2002
			US 6235742 B1	22-05-2001
EP 1097706	A	09-05-2001	AU 7140700 A	17-05-2001
			AU 7140800 A	17-05-2001
			AU 7140900 A	10-05-2001
			AU 7141100 A	10-05-2001
			CN 1320426 A	07-11-2001
			CN 1328824 A	02-01-2002
			CN 1322526 A	21-11-2001
			CZ 20004106 A3	17-04-2002
			CZ 20004107 A3	17-04-2002
			CZ 20004110 A3	17-04-2002
			EP 1097706 A1	09-05-2001
			EP 1097707 A1	09-05-2001
			EP 1097718 A1	09-05-2001
			EP 1097719 A1	09-05-2001
			HU 0004347 A2	28-06-2001
			HU 0004348 A2	28-06-2001
			HU 0004349 A2	28-06-2001
			HU 0004350 A2	28-06-2001
			JP 2001213802 A	07-08-2001
			JP 2001206855 A	31-07-2001
			JP 2001247478 A	11-09-2001
			JP 2001247479 A	11-09-2001
			NO 20005618 A	09-05-2001
			NO 20005661 A	09-05-2001
			NO 20005662 A	09-05-2001
			NZ 508006 A	28-06-2002
			NZ 508007 A	28-06-2002
			NZ 508011 A	28-06-2002
			NZ 508012 A	28-06-2002
			PL 343753 A1	21-05-2001
			PL 343754 A1	21-05-2001
			PL 343755 A1	21-05-2001
			SK 16702000 A3	02-07-2002
			SK 16712000 A3	02-07-2002
			SK 16722000 A3	10-09-2002
WO 02062799	A	15-08-2002	WO 02062799 A1	15-08-2002
			WO 02062798 A2	15-08-2002
			US 2002169175 A1	14-11-2002
EP 0201188	A	17-12-1986	US 4666908 A	19-05-1987
			EP 0201188 A2	17-12-1986
			JP 61236778 A	22-10-1986
US 3939161	A	17-02-1976	NONE	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/04385

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0012504	A	09-03-2000	DE	19838705 A1		02-03-2000
			AU	5516399 A		21-03-2000
			CA	2342109 A1		09-03-2000
			WO	0012504 A2		09-03-2000
			EP	1107968 A2		20-06-2001
			JP	2002523507 T		30-07-2002
			US	6458796 B1		01-10-2002
<hr/>						

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (2007)